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 (Under the direction of Dr. Nobuyo Maeda, PhD) 
The dominant-negative P467L mutation in peroxisome proliferator activated receptor-γ (PPARγ) 
was identified in insulin resistant patients with hyperglycemia and lipodystrophy.  However, mice 
carrying the corresponding Pparg-P465L mutation have normal insulin sensitivity, with mild 
hyperinsulinemia.  I hypothesized that murine Pparg-P465L mutation leads to covert insulin 
resistance, masked by hyperinsulinemia, to retain normal plasma glucose.  I introduced in 
Pparg
P465L/+ mice,  Ins2-Akita mutation that causes islet apoptosis to lower plasma insulin.  Unlike 
Ins2




Akita/+ females have aggravated hyperglycemia, smaller islets, reduced plasma 
insulin and impaired insulin sensitivity.  Enhanced gluoconeogenesis, due to reduced plasma 
insulin, in PpargP465L/+Ins2Akita/+ females compared to Ins2Akita/+ littermates, contributes to their 
fasting hyperglycemia. While liver and skeletal muscles remain sensitive, adipose tissue is resistant 
to insulin.  PpargP465L/+Ins2Akita/+ mice have smaller fat depots composed of larger adipocytes 
suggesting impaired lipid storage with subsequent hepatomegaly and hypertriglyceridemia.   
 iii 
The increasing prevalence of obesity and insulin resistance and its negative impact on 
atherosclerotic cardiovascular disease is of major concern.  In the second part of my study, I 
hypothesized that the L/+ mutation will worsen atherosclerosis in Apoe-/- mice.  Despite a 
consistent increase in blood pressure, PPARγP465L/+ mutation did not affect plaque size in Apoe-/- 
mice fed normal chow or high-fat-diet.  Gene expression studies revealed significantly increased 
ABCA-1 and decreased CD-36 in PPARγP465L/+;Apoe-/- macrophages compared to Apoe-/- 
littermates, suggesting reduced lipid accumulation.  Cultured PPARγP465L/+;Aoe-/- macrophages, 
had a significant reduction in DiI-labeled-VLDL uptake, compared to Apoe-/- macrophages.  It is 
likely that balance between increased blood pressure with its pro-atherogenic potential and 
macrophage athero-protective phenotype results in an unchanged plaque.  Bone marrow transfer 
experiments to investigate the role of PPARγP465L/+ mutation specifically in the macrophage 
showed a trend towards decrease in plaque size in mice reconstituted with PPARγP465L/+;Apoe-/- 
macrophages.   
Thus, I have established the causative link between PPARγP465L mutation and insulin resistance 
phenotype, consolidating the crucial role of PPARγ in diabetes.  PPARγP465L mutation, however, 
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The nuclear hormone receptor super-family consists of several structurally related members that 
have a diverse array of biological functions [1].  Some of the prominent members of this family 
include the estrogen, progesterone, glucocorticoid and thyroid hormone receptors.  These 
molecules share a structural organization, which consists of an N-terminal, DNA-binding domain 
and a C-terminal, ligand-binding domain.  The nuclear hormone receptors bind to their specific 
ligands and transcriptionally control numerous genes in several different gene networks.  The 
liganded nuclear hormone receptors recognize a unique transcription enhancer sequence, known as 
the hormone response element, and regulate the transcription of downstream genes.  In addition to 
their dedicated ligands, nuclear hormone receptors work with several co-activator and co-repressor 
proteins and transcription factors to induce or suppress their target genes.   
Peroxisome Proliferator Activated Receptors (PPARs) belong to the superfamily of nuclear 
hormone receptors and three major isoforms, encoded by separate genes, have been discovered to 
date - PPARα, PPARδ/β and PPARγ [2].  In contrast to the typical members, such as estrogen 
receptor with its known exclusive ligands, PPARs are considered as orphan receptors since the 
unique, high-affinity, endogenous ligands for the PPAR isoforms remain elusive.   
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1.1 Discovery of PPARs 
Continued exposure to hypolipidemic drugs, such as clofibrate, certain herbicides and plasticizers, 
was known to cause peroxisome proliferation and induce microsomal compartment in mouse and 
rat liver parenchymal cells eventually leading to hepatic tumors [3, 4].  These peroxisome 
proliferators did not damage DNA and are structurally quite different from each other.  This led to 
a proposition by Reddy and Rao in 1986 that the responses to peroxisome proliferators and 
stimulation of genes encoding fatty acid oxidation enzymes is brought about by soluble receptor/s 
[5].  The experimental evidence for this potential receptor mediated mechanism was provided by 
previous work of Goldfischer and Reddy in 1984, who demonstrated specific soluble binding sites 
for peroxisome proliferators in liver and kidney cell extracts [6].  Eventually, a mouse receptor 
mPPAR (mouse peroxisome proliferator activated receptor) was isolated and was shown to be 
activated by peroxisome proliferators [7].  In 1992, Dreyer et al cloned three novel members from 
the nuclear hormone receptor superfamily that were structurally and functionally related to 
mPPAR.  These new sequences isolated from Xenopus laevis were named xPPARα, β, and γ.  
These novel members were shown to be transcription factors and mediated the peroxisome 
proliferator-induced response of acyl coenzyme A (acyl-coA) oxidase gene, an important enzyme 
in the peroxisomal fatty acid oxidation.  The human peroxisome proliferator activated receptor 
(hPPAR) was soon cloned from a human liver and fat cell cDNA library [8, 9].  Similar to 
Xenopus and mouse PPAR, the hPPAR was also shown to transactivate the acyl-coA oxidase 
PPAR response element with the prototypical peroxisome proliferators, including clofibrate, 
 
 4 
nafenopin and WY-14643 [8].  Subsequently, the presence and differential expression of the three 
PPAR isoforms was confirmed in mice and humans [8, 10, 11].   
1.2 Peroxisome Proliferator Activated Receptor-γ 
Among the three PPAR isoforms, PPARγ is essential for adipocyte differentiation, glucose and 
lipid metabolism, inflammation, and regulation of cell growth [12]. PPARγ functions as a 
transcription factor and is most abundantly expressed in adipocytes and is also found in liver, large 
intestine, β cells of pancreatic islets, macrophages, skeletal muscle and kidney [13, 14].  
Thiazolidinedione drugs, such as Rosiglitazone, which were already in use as insulin sensitizers for 
treating diabetic patients, were found to be specific, high affinity ligands for PPARγ.  
1.3 PPARγ Gene and Protein Structure 
PPARγ exists as four protein isoforms - PPARγ1 to PPARγ4 - derived from a single gene through 
differential promoter usage and different leader exons [15].  The PPARG gene is located on 
chromosome 3 in humans and is composed of nine exons which span more than 100 kb [14, 16].   
All four transcripts contain six common exons (exons 1-6).  The human PPARγ1 mRNA is coded 
by 8 exons.  Exon A1 and A2 comprise the 5’-untranslated region of human PPARγ1 and are 
followed by exons 1 to 6.  PPARγ2 consists of an additional 28 amino acids, which are encoded by 
exon B.  As shown in figure 1.1, mouse Pparg is located on chromosome 6 and extends more than 
105 kb [17].  Mouse PPARγ-2 has an additional 30 amino acids in the N-terminus of the molecule 
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compared to mouse PPARγ1.  Mouse PPARγ1 is composed of eight exons (A1, A2 and 1-6), 
whereas mouse PPARγ2 consists of seven exons (B1, 1-6) [17]. 
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 Figure 1.1: Schematic of the mouse PPARγ gene and mRNA structures of mouse PPARγ1 
and mouse PPARγ2.  The 5’-UTR of m PPARγ1 is encoded by exon A1 and A2.  Exon B1 
codes for the 5’-UTR of m PPARγ2 and 30 additional amino acids in the N-terminal of the 
protein.  (adapted from Zhu,Y et al PNAS, 1995, ref#17) 
D  
ATG 
AF-1 DBD LBD AF-2 
5’UTR 3’UTR 
mPPARγ1 
A1 A2 B1 1 2 3 4 5 6 






Considering the relative amounts of transcripts, PPARγ2 is the most important form of the protein 
and is almost exclusively expressed in the adipose tissue with some expression in the pancreatic 
islets [18].   PPARγ1 and PPARγ3 are more ubiquitously expressed. Little information is available 
about the PPARγ4 isoform, however it seems to be important in adipocytes.  
 
The human and mouse PPARγ proteins demonstrate a 99% similarity and 95% identity in their 
amino acids [14].  PPARγ is one of the typical members of the nuclear receptor superfamily. Thus, 
the protein structure consists of an N-terminal domain, which has a ligand-independent 
transcriptional activation function (AF-1), a DNA binding domain (DBD) and a C-terminal ligand 
binding domain (LBD) with a ligand-dependent transcriptional activation function (AF-2) [19, 20]. 
The D site is a docking domain for cofactors, which can be different co-activator and co-repressor 
proteins.   
1.4 PPARγ Ligands 
Many compounds, like polyunsaturated fatty acids and prostaglandins, bind to PPARγ [21].  Since 
these compounds exist in cells at much lower concentrations than necessary for effective PPARγ 
binding, their ability to activate PPARγ with significant downstream effects and consequently their 
role as a true endogenous ligand are debatable.  Out of all the known nuclear receptors, PPARs 
have a ligand binding domain with a very large volume, which measures about 1300 Å3[22].  This 
large ligand binding domain allows PPARγ to bind to a wide variety of ligands, which vary in size 
and shapes.  Thus, polyunsaturated fatty acids, oxidized fatty acids, eicosanoids, and prostaglandin 
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J2 are some of the compounds known to be the natural ligands of PPARγ (Table 1.1) [23, 24].  
PPARγ is activated by synthetic compounds, including Thiazolidinediones (TZD), with higher 
affinity and kd values at nanomolar levels [25].  TZDs are one of the principle drugs in the 
treatment of diabetes mellitus [21] and are known to increase insulin sensitivity and improve 
















Medium (low Micromolar) 
Natural/Endogenous Linoleic acid 
Arachidonic acid 
Low (high Micromolar to 
Millimolar) 
 
Table 1.1: PPARγ agonsists and their relative binding affinity. 15d-PGJ2, 15d-prostaglandin 
J2; 9-HODE, 9-hydroxy octadecadienoic acid; 13-HODE, 13-hydroxy octadecadienoic acid; 
15-HETE, 15-hydroxy eicosatetraenoic acid; oxLDL, oxidized low density lipoprotein 
(adapted from Bishop-Bailey 2003, ref#28). 
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1.5 Mechanism of Action of PPARγ 
Transactivation:  PPARγ regulates the function of its target genes via activation of transcription.  
It heterodimerizes with Retinoid X Receptor-α (RXRα) and binds to the Peroxisome Proliferator 
Response Element (PPRE) in the promoter region of the target genes [21].  Most PPREs are 
degenerate variants of a direct repeat of the hormone response element sequence (AGGTCA) 
separated by one base pair [29].  In the absence of the ligand, the PPARγ /RXR heterodimer is 
bound to co-repressor proteins, such as histone deacetylases and chromatin-modifying factors.  
This complex binds to the PPRE in the regulatory region of the target gene leading to active 
silencing of transcription.  Binding of a ligand to the LBD causes a conformational change in 
PPARγ, release of repressor molecules, and recruitment of co-activator/s, resulting in an induction 
in the transcription of the downstream genes (Figure 1.2).  The co-activators include proteins 
which modify chromatin structure and bridge PPARγ to the transcription machinery.  The majority 
of these downstream genes such as Glut-4, Glut-2, adipocyte fatty acid binding protein (aP2), 
phosphoenolpyruvate carboxykinase (PEPCK) and insulin receptor substrate (IRS-2) are involved 
in glucose and lipid metabolism [21]. Thus, mutations in PPARγ may alter the glucose homeostatic 




Figure 1.2: Schematic of PPARγ transactivation.  Upon ligand binding in the presence of co-
activator proteins, the PPARγ/ RXR heterodimer binds to the PPRE of its target genes to 
induce transcription (adapted from Tsai et al, 2005, ref#30). 
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Transrepression:  In addition to the direct regulation of transcription, another mechanism of action 
of PPARγ termed transrepression has been proposed and comprehensively studied in macrophages 
[31].  In the transrepression pathway, PPARγ has been shown to interact with other transcription 
factors, such as NF-κB and AP1.  An inflammatory stimulus induces the transcription of pro-
inflammatory genes via transcription factors, such as NF-κB andAP1, due to association of these 
factors with the inflammatory response element (IRE) [31].  PPARγ with its ligand forms a part of 
an inhibitory complex (IC) that reduces the expression of the pro-inflammatory genes and exerts an 
anti-inflammatory action (Figure 1.3).  In this pathway, PPARγ does not need to form a 
heterodimer with RXR and does not require a PPRE.  The inhibitory complex consists of post-
transcriptionally modified PPARγ, SUMO (small ubiquitin-like modifier)-protein ligases, 
ubiquitin-conjugating enzymes, and proteins that link these with co-repressors to suppress NF-κB 
and AP1 [32].  The first step of the trans-repression pathway begins with ligand-dependent 
SUMOylation of the PPARγ ligand binding domain, which targets PPARγ to nuclear receptor 
corepressor (NCoR)-histone deacetylase -3 (HDAC3) complexes on the promoter of inflammatory 
genes.  This prevents recruitment of the ubiquitylation/19S proteosome machinery that is 
responsible for a signal-dependent removal of corepressor  complexes required for gene activation.  
Thus, NCoR complexes are not cleared from the promoter and the transcription of the target pro-




Figure 1.3:  Mechanism of action of PPARγ: transrepression pathway by which PPARγ 
regulates the expression of inflammatory genes is primarily characterized in the macrophage 
(Ketsawatsomkron, 2010, ref#32). 
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The functional impact caused by PPARγ is complicated by the fact that more than one compound 
has been shown to act as a ligand and multiple compounds are known to act as co-activators and 
co-repressors.  Unique conformational changes in response to a particular ligand may allow for the 
recruitment of a specific group of co-activators, resulting in the induction of a subset of genes in 
response to that ligand.  The relative availability of the ligands and co-activators in a particular cell 
type and under specific metabolic states may also contribute to the resulting transactivation/ 
transrepression of the target genes.     
1.6 Biological Functions of PPARγ 
PPARγ in adipogenesis: PPARγ is essential for the formation of adipose tissue in vivo [12, 33] .  
In addition, PPARγ has been shown to have a role in glucose metabolism and insulin sensitivity, 
inflammation and growth regulation.  Below, I discuss a few of the biological processes in which 
PPARγ plays a critical role, thus highlighting the importance of this molecule in metabolism.       
PPARγ PPARγ is crucial for the differentiation of adipose tissue and for the deposition of 
triglycerides in adipocytes.  PPARγ is expressed early in adipogenesis in the fibroblast-like 
preadipocytes that are destined to become mature adipocytes.  PPARγ expression is brought about 
by transcription factors C/EBPβ and C/EBPδ with availability of insulin and steroid hormones [34, 
35].  In a well defined positive feed back loop, C/EBPα increases the expression of PPARγ in the 




Figure 1.4: Schematic of adipocyte differentiation from a fibroblast like pre-adipocyte cell.  









The over expression of PPARγ by itself can induce the conversion of cultured fibroblasts (NIH-
3T3 cells) into adipocytes [36].  Additionally, PPARγ and C/EBPα can together induce trans-
differentiation of myoblasts into adipocytes [37].  Consistent with these over-expression in-vitro 
studies, Rosen et al reported that when embryonic stem cells lacking both copies of PPARγ were 
subjected to an adipose differentiation protocol, no adipocytes developed [38].  PPARγ knockout 
pups, rescued by tetraploid aggregation to circumvent placental pathology, have complete absence 
of adipose tissue (Table 1.3#1) [12].   Mice with 25% normal PPARγ expression have a 
significantly reduced adipose tissue mass [39] (Table 1.3#4) and a severe lipodystrophy phenotype 
has been demonstrated in mice specifically lacking PPARγ2, the isoform predominantly expressed 
in white adipose tissue [40] (Table 1.3#3).   
A number of point mutations in PPARγ have been reported to occur within human populations.  
These mutations, which affect adipose tissue distribution, further confirm the crucial role of 
PPARγ in adipose physiology.  For example, heterozygous P467L and V290M mutations in the 
ligand binding domain of PPARγ were identified among insulin resistant patients.  The mutations 
act in a dominant-negative fashion, since heterozygous presence of this mutation reduces 
transactivation by PPARγ to significantly less than 50%.  These patients have normal total adipose 
tissue weights, however, the fat distribution is altered resulting in increased intra-peritoneal fat 




Gene Function Reference 
Adipose Tissue 
aP2/ Adipose fatty acid 
binding protein 
Intracellular fatty acid 
binding 
Wu, 1995, Genes Dev 
Adiponectin Adipose-derived, insulin 
sensitizing cytokine 
Iwaki, 2003, Diabetes 
Acyl CoA synthetase Fatty acid transport, 
lipogenesis and catabolism 
Martin, 1997, JBC 
FATP-1/ Fatty acid 
transporter, member 1 
Regulation of intracellular 
fatty acid concentration 




Glyceroneogenesis Tontonoz, 1995,  
Mol Cell Biol 
Macrophage 
ABCA-1/ATP-binding 
cassette protein-1  
Choleserol efflux Akiyama, 2002,  
Mol Cell Biol 
CD-36/ Scavenger receptor Lipid uptake Akiyama, 2002,  
Mol Cell Biol 
Apolipoprotein E Receptor-mediated 
lipoprotein uptake 
Akiyama, 2002,  
Mol Cell Biol 
CCR2/  
Chemokine Receptor 2 
Monocyte recruitement to 
vessel wall 
Han, 200, JCI 
Liver 
Glucokinase Glucose transporter  Kim, 2004, Diabetes 
Pancreas 
Glut-2 Glucose sensor in β-cells Kim, 2000, Diabetes 
Glucokinase Glucose sensor in β-cells Kim, 2000, Diabetes 




Table 1.2:  PPARγ target genes. 
Skeletal Muscle 
Glut-4 Insulin-responsive glucose 
transporter 
Ezaki, 1997, Biochem 
Biophys Res Commun 





Mouse Model Reference Phenotype 
1. PPARγ -/- Barak Y, 1999,  
Mol Cell [12] 
- Embryonic lethal due to placental and 
cardiac defects 
- Pups rescued by tetraploid aggregation with 
wild type placentas had absence of all types 
of adipose tissue 
2. PPARγ +/- 
with HFD 
Kubota N, 1999, 
Mol Cell [55] 
- Absence of adipocyte hypertrophy in 
response to HFD 
- Protection against HFD induced insulin 




2003, PNAS [40] 
- Predominantly white adipose tissue 
knockdown of PPARγ 
- Growth retardation, severe lipodystrophy, 
hyperlipidemia 
- mild glucose intolerance due to 
compensatory effective lipid oxidation in 
skeletal muscle 
4. PPARγ c/- 
(25% of WT 
expression) 
Tsai YS, 2009,  
Mol Endocrinol 
[39] 
- Reduced body weight and reduced total fat 
mass due to selective reduction in 
perigonadal fat depot  
- Insulin resistance 
- Dyslipidemia, increased ectopic lipid 




He W, 2003, 
PNAS [52] 
- Adipocyte hypocellularity and hypertrophy, 
increased plasma NEFA and TG, decreased 
plasma leptin and adiponectin 
- Increased hepatic gluconeogensis and 
insulin resistance, corrected by TZD 





2003, JBC [53] 
- Increased adipocity, insulin resistance, 
hyperlipidemia and fat intolerance 
- Worsened hyperlipidemia, TG clearance 
and skeletal muscle insulin resistance on 





2003, Nat Med 
[54] 
- Glucose intolerance and insulin resistance 










Rosen ED, 2003, 
MCB [61] 
 
- Significant islet hyperplasia on normal 
chow diet 
- Markedly blunted expansion of islets in 
response to HFD 
- No difference in plasma glucose and 






2007, Nature [82] 
- Impaired alternative macrophage activation 







Kanda, 2009,  
JCI [92] 
- Decreased adiposity and increased insulin 
sensitivity on HFD 




PPARγ in Insulin Secretion and Insulin Sensitivity:  The increased occurrence of insulin 
resistance in obese individuals, the use of TZDs as anti-diabetic drugs, and the role of PPARγ in 
pre-adipocyte differentiation and triglyceride deposition in adipocytes suggest a link between 
PPARγ and maintenance of normal plasma glucose.  As stated earlier, many of the genes involved 
in peripheral insulin sensitivity are downstream targets of PPARγ (Table 1.2).  For example, 
Glucose Transporter 4 (GLUT-4), which is transcriptionally activated by PPARγ, is a major 
insulin-responsive glucose transporter in skeletal muscle and adipose tissue, organs which are 
responsible for the post-prandial clearance of glucose from the plasma [50].   
Mice that have reduced PPARγ expression globally or have tissue-specific PPARγ deficiency show 
altered insulin sensitivity.  A global PPARγ deletion is embryonic lethal [12]; however, a specific 
deletion in PPARγ2, which is mostly expressed in adipose tissue, results in severe lipodystrophy, 
hyperlipidemia and a mild glucose intolerance [40] (Table 1.3#3).  Glucose intolerance is mild in 
these mice due to a compensatory increase in lipid oxidation by skeletal muscle.  The phenotypes 
of various PPARγ mutant mouse models have been discussed in Table 1.3 – “Adipose tissue and 
insulin sensitivity related phenotypes in various PPARγ mutant mice”.   
The tissue-specific knockouts of PPARγ have also highlighted the contribution of individual 
organs to the maintenance of normal insulin sensitivity globally at the animal level and specifically 
in individual tissues.  The adipose tissue-specific PPARγ knockout mice display a reduced 
buffering capacity for lipids in the PPARγ deficient adipocytes, resulting in hyperlipidemia on 
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normal chow and hepatic steatosis with high fat feeding.  In addition, these mice had a insulin 
resistance phenotype restricted to the liver and increased hepatic gluconeogenesis [52] (Table 
1.3#5).  Glucose uptake in the skeletal muscle of adipose-specific PPARγ deficient mice was not 
affected. Mice lacking PPARγ specifically in the liver display hyperlipidemia, increased adiposity 
and global insulin resistance.  These mice, however, responded to hypoglycemic and 
hypolipidemic properties of rosiglitazone, consistent with the idea that the adipose tissue is the 
primary site of action of the PPARγ agonist TZDs.  When liver PPARγ was ablated from 
lipoatrophic A-ZIP/F-1 mice (lacking adipose tissue), there was worsening of hyperlipidemia and 
insulin resistance, but reduced hepatic steatosis compared to liver specific PPARγ knock-out, non 
A-ZIPF-1 mice.  Further, in A-ZIP/F-1 mice lacking PPARγ in liver, hypoglycemic and 
hypolipidemic action of PPARγ agonsist rosiglitazone was abolished, indicating that in the absence 
of adipose tissue, hepatic PPARγ is essential for rosiglitazone action [53] (Table 1.3#6).  Hevener 
et al showed that the deficiency of PPARγ in skeletal muscle causes progressive insulin resistance 
in this tissue [54] (Table 1.3#7).   
Based on these mouse models of PPARγ, several important deductions can be made.  Adipose 
tissue emerges as the primary site of action of PPARγ agonists and optimal levels of PPARγ are 
essential for lipid deposition in the adipocytes.  This buffering function compartmentalizes the 
excess lipids in adipose tissue and protects the liver from lipid toxicity, which can interfere with 
maintenance of insulin sensitivity.  Second to adipose tissue, PPARγ is essential for the appropriate 
amount of lipid accumulation in the hepatocyte and also for glucose transport into the cell.  
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Compared to adipose tissue, skeletal muscles express lower levels of PPARγ.  However, skeletal 
muscle is the single most important organ for post-prandial glucose uptake in response to insulin.  
Glut-4, the major glucose transporter in skeletal muscle is transcriptionally activated by PPARγ.  
Thus, the absence of PPARγ in skeletal muscle affects glucose handling and insulin sensitivity.  
Surprisingly, mice with a heterozygous deficiency in PPARγ were protected from a high fat diet 
induced insulin resistance [55] (Table 1.3#2).  However, Tsai et al recently examined the effects of 
quantitative changes in PPARγ levels on insulin sensitivity in mice.  We generated mice with a 
global reduction in PPARγ levels to 25% of wild type by destabilizing its 3’-UTR and 
demonstrated that this level of reduction results in smaller adipose tissue mass, hyperlipidemia, 
increased lipid deposition in skeletal muscle and insulin resistance [39] (Table 1.3#4).   
Mutations in PPARγ are rare events, but seem to have a considerable impact on insulin sensitivity. 
Among others, loss of function mutations P467L and V290M in human patients are associated 
with reduced insulin sensitivity [56]. On the other hand, a fairly common P12A polymorphism 
with reduced PPARγ activity is associated with improved insulin sensitivity [57].  
In addition to peripheral tissues, PPARγ appears to play a role in regulating glucose uptake in the 
beta cells of the pancreas. Treatment of rat primary islets for three days with Troglitazone (a TZD 
drug) resulted in an increase in GLUT-2 expression [26].  Glucose transporter GLUT-2, which is 
considered to be the glucose sensor in the pancreatic islets, has a functional PPRE [26].  Thus, 
PPARγ can potentially increase insulin secretion from the β-cells of the pancreatic islets in 
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response to increased concentration of glucose.  Supporting this possibility, Xu et al demonstrated 
that PPARγ activation increased Glut2 expression, increased glucose stimulated insulin secretion 
(GSIS), increased fatty acid oxidation and decreased accumulation of triglycerides in INS-1 cells 
[58, 59].  In contrast, Ravnskjaer et al demonstrated that when PPARγ is over-expressed in INS-1E 
cells, it increases fatty acid uptake and deposition of triglycerides in these cells.  This, in turn, 
results in a reduction in glucose stimulated insulin secretion from these cells.  They propose that in 
conditions of hyperglycemia and/or obesity, β-cells over-express PPARγ, resulting in increased 
triglyceride accumulation and impaired insulin secretion [60].  Thus, the specific effect of PPARγ 
activation on GSIS is still debatable.  
Rosen et al generated mice lacking PPARγ specifically in the β-cells of the pancreatic islets by 
crossing mice with floxed PPARγ and mice carrying a Cre transgene driven by the rat insulin 
promoter (Table1.3#8) [61].  The mice lacking PPARγ selectively in the β-cells have a significant 
islet hyperplasia on a normal chow diet.  Additionally, the normal expansion of islets in response to 
high fat diet is markedly blunted in these mice.   However, there was no difference in plasma 
insulin levels compared to wild type mice and the glucose homeostasis remained unchanged from 
wild type regardless of the diet.  Recent in-vivo data suggest that PPARγ activation can improve 
islet function in diabetic mice [62].  Evans-Mollina showed that when diabetic mice (due to high 
fat diet or due to deficiency in leptin receptor) were treated with Pioglitazone by oral gavage for 4-
6 weeks, there was significant reduction in their hyperglycemia.  This was attributed to increased 
circulating insulin levels in mice and enhanced glucose stimulated insulin secretion demonstrated 
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in-vitro.  The improved islet function was associated with significant up-regulation of islet genes, 
including Ins1/2 and Glut-2.  The authors showed a 2-3 fold increase in euchromatin marker 
histone H3 dimethyl-Lys4 on the Ins1/2 and Glut-2 promoters and increased nuclear occupancy of 
islet methyltransferase Set7/9.  Using in-vitro experiments, these favorable effects on islet gene 
chromatin structure were shown to be due to reduced endoplasmic reticulum stress in the presence 
of Pioglitazone. Although the direct mechanism by which PPARγ regulates insulin secretion is not 
entirely clear, there is convincing data implicating an involvement of PPARγ in insulin secretion 
from pancreatic islets.   
PPARγ in Blood Pressure Regulation:  In addition to its role as an important regulator of 
adiposity, PPARγ has been shown to play a role in the maintenance of blood pressure.  Patients 
heterozygous for a P467L mutation in PPARγ have hypertension at an early age.  Although the 
individual mutations are a rare occurrence, hypertension is associated with many of the point 
mutations (P467L, V290M, F388L, R425C) in the ligand binding domain of PPARγ, thus 
consolidating its role in the regulation of blood pressure [51, 63, 64].  Calnek et al showed that 
treatment of cultured human endothelial cells with PPARγ ligands 15d-PGJ2 or ciglitazone 
increased release of vasodilator nitric oxide (NO), without increasing endothelial nitric oxide 
synthase (eNOS) expression [65].  Further, PPARγ specific siRNA and PPARγ antagonist 
GW9662 significantly reduced 15d-PGJ2, ciglitazone and rosiglitazone induced NO release from 
cultured endothelial cells, establishing that the effect of these compounds is mediated by PPARγ 
[66].  In addition to these in-vitro studies, two independent groups demonstrated the involvement 
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of PPARγ in blood pressure regulation in mice.  Using mice selectively deficient in PPARγ in the 
endothelial cells, Nicol et al showed that the basal levels of blood pressure on normal chow diet are 
not different in these mice when compared to wild type controls.  However, there is a significant 
increase in blood pressure in high fat fed mice lacking PPARγ in their endothelial cells and this 
increase is not corrected by rosiglitazone treatment [67] (Table 1.4#4).  In another study, 
Kleinhenz et al showed that endothelium specific PPARγ knockout mice have elevated baseline 
blood pressure due to reduction in the production of vasodilator nitric oxide and impaired aortic 











- Hypotension not corrected by salt 
loading  
- Vasculature more sensitive to 
endothelium-dependant relaxation caused 
by muscarinic stimulation 
- Impaired VSMC contraction in 
response to alpha-adrenergic agents 






- Increased BP 
- Intact response of aorta to Ach, 
increased contraction to endothelin 1, 
serotonin and PGF2α 
- Impaired Ach-induced dilatation in 
cerebral blood vessels and increased 
superoxide 
- Reduced maximally dilated diameter of 
cerebral arteriole, increased wall 









- High baseline BP but similar increase 
in SBP (compared to WT) in response to 
angII infusion 









- No increase in BP with normal chow 
and high salt diet 
- Significant elevation of SBP with HFD, 
not corrected by rosiglitazone 
5. Endothelium and 
bone marrow-
specific PPARγ-/- 
Kanda, 2009,  
JCI [92] 
- Increased BP on HFD 









Beyer, 2008,  
Circ Res 
[94] 
- Impaired Ach induced dilatation of basilar 
artery after 12 week HFD, improved by 
treatment with superoxide scavanger 
- Slight elevation in baseline BP, augmented 
pressor response to angII 






- Reduced BP 
- Reduced NE-stimulated aortic contraction, 








- Systolic hypertension 
- Impaired aortic ring reactivity to 
endothelium-derived or exogenous NO 
- Increased vasoconstrictor response to 
serotonin, endothelin 1 but modest decrease 
with PE 
Vascular hypertrophy and remodeling of 
micro-vasculature 
Table 1.4: Vascular and Blood Pressure Phenotypes in PPARγ Mutant Mice Ach, 
acetylcholine; ang II, angiotensin II, BP, blood pressure; HFD, high fat diet; NO, nitric 
oxide; PE, phenylephrine; SBP, systolic blood pressure; VSMC, vascular smooth muscle cell. 
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This phenotype was also associated with an increase in the parameters of oxidative stress in blood, 
such as reactive oxygen species (ROS), plasma concentration of cysteine (Cys), cystine (CySS) 
and the Cys/CySS redox potential (Table 1.4#3) [68].  Thus, PPARγ in the endothelial cells is 
essential for blood pressure regulation and its absence can result in a hypertensive phenotype.  In 
addition to the endothelium, vascular smooth muscle cells are shown to express PPARγ [69].  
Halabi et al demonstrated that mice expressing the dominant negative P465L and V290M 
mutations in PPARγ, specifically in the vascular smooth muscle cells, have elevated blood pressure 
levels.  These mice show a severely impaired aortic reactivity to endothelial-derived or exogenous 
nitric oxide (Table 1.4#8) [70].  Based on this data, PPARγ in vascular smooth muscle cell is 
necessary to mediate vasodilator signals originating in the endothelium, such as NO release.  
However, lack of PPARγ in vascular smooth muscle cell results in reduced blood pressure (Table 
1.4#7) [71].  These mice had a reduced aortic contraction in response to nor-epinephrine and an 
increase in β-adrenergic agonist mediated vasodilatation.  Several mouse models, as discussed in 
Table#1.4, titled “Vascular and Blood Pressure Phenotypes in PPARγ Mutant Mice”, have been 
generated to understand the mechanism by which PPARγ affects blood pressure.  These models 
highlight the actions of PPARγ in endothelium and vascular smooth muscle cells, the two cell 
types which can modulate flow and pressure in the blood vessels.  Taken together, these in vitro 
and in vivo experiments suggest that an increase in PPARγ activity has a beneficial effect on 
vascular function.  In addition to studying the effect of PPARγ on blood pressure regulation, these 
mouse models can also be used successfully to study the effects of alterations in PPARγ activity on 
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blood pressure and the indirect effect of the change in blood pressure on chronic disease processes, 
such as atherosclerosis.   
PPARγ in Macrophage Function and Atherosclerosis:  An oxidized alkyl phospholipid, 
hexadecyl azelaoyl phosphatidylcholine, a component of oxidized low density lipoproteins, has 
been shown to bind to PPARγ with a relatively high affinity (kd approximately 40 nM), similar to 
that reported for rosiglitazone [72].  This highlights a new link between PPARγ, low-density 
lipoproteins and the fate of atherosclerotic plaques.  The increased prevalence of obesity, 
hypertension and insulin resistance in the population exacerbates atherosclerosis and 
cardiovascular disease outcomes.  Many diabetic patients are being treated with insulin sensitizer 
drugs TZDs, which have been shown to reduce the atherosclerotic lesion size in human patients.  
Similarly, using mouse models of atherosclerosis lacking apolipoprotein E (apoE) and/or low 
density lipoprotein receptor (LDLR), several studies have established the anti-atherosclerotic 
effects of PPARγ agonists [73, 74, 75].    
Macrophages are a crucial element in the formation and propagation of an atherosclerotic plaque.  
The foam cells found in the core of a plaque are lipid-laden macrophages and PPARγ plays an 
important role in the lipid accumulation in these cells by influencing the lipid uptake as well as 
efflux [45, 76, 77].  The scavenger recptor CD36, which is responsible for uptake of lipid by the 
macrophage, is shown to be transcriptionally activated by PPARγ [77] in response to 15-PGJ2 or 
TZD treatment.  9- and 13-HODE present in oxidized LDL can also activate PPARγ (kd in a 10-20 
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µM range) [78].  In a proposed “PPARγ cycle” by Nagy et al, oxidized LDL would induce activity 
of PPARγ resulting in increased expression of CD36 consequently increasing the oxidized LDL 
uptake by the macrophage [74, 78].  Thus, this cycle can potentially promote formation of foam 
cells and atherosclerosis.  On the other hand, PPARγ activates a pathway of cholesterol efflux from 
the macrophage [79].  Ligand activation of PPARγ results in increased expression of ABCA-1, a 
molecule that facilitates cholesterol transfer from cells to high density lipoprotein (HDL), via 
induction of LXRα.  Babaev et al demonstrated a significant increase in atherosclerosis when 
PPARγ null bone marrow was transplanted in low density lipoprotein receptor knockout (LDLR-/-) 
mice and established the protective effect of PPARγ-mediated induction of ABCA-1 and the 
cholesterol efflux pathway in the macrophages [80].      
The transrepression pathway of PPARγ function has been primarily characterized in the 
macrophage, where PPARγ is actively involved in regulating their inflammatory properties.  In the 
basal state, inflammatory genes, such as inducible nitric oxide synthase (iNOS) and chemokine 
CC-chemokine ligand 2 (CCL2) are repressed by the inhibitory complex that includes PPARγ [31].  
PPARγ expression in human and mouse monocytes directly inhibits CC chemokine receptor 2 
(CCR2) expression and suppresses monocyte chemoattractant protein (MCP-1)-mediated 
chemotaxis [46].  Also, monocytes that are pretreated with PPARγ agonists have reduced adhesion 
to endothelial cells [81].  Consistently, macrophages obtained from macrophage-specific PPARγ 
knockout mice demonstrate increased migration and have a higher CCR2 expression compared to 
wild type macrophage [80]. 
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In addition to its anti-inflammatory actions, PPARγ plays an important role in macrophage 
differentiation.  Classically activated M1 macrophages produce pro-inflammatory cytokines; 
whereas alternative activation produces M2 macrophage, which secrete anti-inflammatory 
cytokines.  A balance between the M1 and M2 phenoytpes is crucial in regulating inflammation in 
atherosclerosis.  Macrophage-specific PPARγ activation has been shown to enhance alternative 
activation and potentially favor the anti-inflammtory actions [82].    
In addition to the macrophage, endothelial cells and vascular smooth muscle cells (VSMC) 
modulate the initiation and propagation of an atherosclerotic plaque.  The role of PPARγ-mediated 
enhancement in NO production by the endothelium not only reduces blood pressure but can also 
potentially modulate the progression of atherosclerosis by directly reducing reactive oxygen 
species.  Finally, Subramanian et al generated VSMC-specific PPARγ knockout and have shown 
that these mice develop enhanced atherosclerosis upon induction with angiotensin II [83].  
Pioglitazone treatment reduced angiotensin II induced atherosclerosis in wild type mice but not in 
mice lacking PPARγ in VSMC.  This emphasizes the importance of PPARγ in VSMC in 
atherosclerosis protection. 
1.6 Mouse Models Used in My Study  
Mouse PPARγP465L mutation:  P465L mutation in PPARγ involves the proline residue in Helix 
12 in the ligand-binding domain of PPARγ in mice [51].  This residue is important for binding to 
ligands and cofactors resulting in significant effects on PPARγ signaling in the presence of the 
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mutation.  PPARγP465L/+ mice (L/+ mice), are heterozygous for codon 465 mutated from CCC 
(proline) to CTG (leucine) in mouse embryonic stem cells using the gene targeting technique 




Figure 1.5: Schematic of PPARγ with the location of P465L mutation. 
Ligand binding domain 
P465L 
C-terminal N terminal 
DNA binding PPARγ 
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In an in-vitro system using the aP2 promoter, which contains a PPRE, it has been shown that the 
mutant P465L allele acts in a dominant negative manner [85]. The mutant protein reduces the 
activity of the wild type protein by more than 50% by blocking its access to the PPREs in 
downstream genes. It is thus reasonable to conclude that the heterozygous P465L/+ animals have 
less than 50% functional PPARγ protein. Homozygous mice with P465L mutation die in-utero, 
establishing that the mutant protein is nonfunctional [84]. This phenotype is very similar to the 
PPARγ null mice which do not survive [12]. Human patients heterozygous for the corresponding 
P467L mutation have high plasma glucose and insulin levels, are hypertensive and have an altered 
fat distribution [51]. L/+ mice heterozygous for the P465L mutation are mildly hypertensive, 
hyperinsulinemic (Figure 1.6) and have an altered fat distribution; however, they have normal 
levels of plasma glucose.  
PPARγ P465L mutation and pancreatic islets: P465L/+ mice (dark bars) have an increased 
mean islet area and increased endocrine cell mass, especially on high fat diet compared to wild 





Figure 1.6: Level of plasma insulin during a glucose tolerance curve in L/+ (dark squares) 
and wild type (open squares) mice on high fat diet. L/+ mice had higher plasma insulin, 




Figure 1.7: Mean islet area.  P465L/+ mice (dark bars) have an increased mean islet area, 
especially on high fat diet compared to wild type animals.  RC, regular/ normal chow; HF, 
high fat (Tsai YS, 2004, JCI, ref#84). 
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This phenotype is in agreement with other evidence in the literature for the role of PPARγ in islet 
physiology. The rescued PPARγ null animals were generated by breeding Mox2 Cre mice and 
floxed PPARγ mice, resulting in the inactivation of PPARγ in the embryo but not in the 
trophoblast.  The rescued PPARγ null mice have bigger pancreatic islets, with significantly higher 
plasma insulin levels in response to glucose load and impaired insulin sensitivity [86]. Mice with 
selective knockout of PPARγ in β-cells of pancreatic islets also have an increase in islet cell mass 
due to β-cell hyperplasia, but did not increase the islet cell mass on high fat feeding [61]. The β-
cell selective knockouts, however, have normal plasma insulin levels. These data suggest that at 
baseline conditions, PPARγ has an inhibitory effect on β-cell proliferation, but it is essential for 
expansion of islet mass induced by obesity. The phenotype of P465L/+ mice suggests that there is 
some impairment in the PPARγ  signaling and that the increased expansion of islets compared to 





Mutation   
Ins2
C96Y or Ins2Akita/+ mutation is an autosomal dominant mutation in the Ins2 gene in mice 
resulting from a G to A transition at nucleotide 1907 in exon 3 of one of the Ins2 alleles [87]. 
Heterozygous Ins2Akita/+ mice with Akita mutation are hyperglycemic (have increased plasma 
glucose levels) due to inadequate production of insulin, particularly severe in male mice. Due to 
the reduced insulin production, Akita mice are considered a model for type 1 diabetes mellitus. 
However, Hong et al recently showed that Akita mice also develop features of type 2 diabetes, 
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including insulin resistance [88]. In the protein product of this mutation, cysteine is substituted by 
tyrosine at the seventh amino acid position in the A chain of Insulin 2 molecule [87]. The insulin 
molecule structurally consists of A and B chains and the above mentioned cysteine is involved in 
the formation of one of the two intra-molecular disulfide bonds that hold the two chains together. 
The destruction of this disulfide bond has a significant impact on the conformation of the protein, 
resulting in misfolding and proteasomal degradation. Mice have another functional insulin gene – 
Ins1. Thus, the heterozygous Akita mice have 3 normally functional insulin alleles and the insulin 
mRNA levels are similar to wild type suggesting no transcriptional impairment. However, the 
amount of proinsulin and insulin proteins is low in the islets of Akita mice, resulting in increased 
plasma glucose levels. The dominant negative effect of this mutation is shown to be due to 
generalized degradation of the organelles involved in the intracellular secretory pathways, stress on 
endoplasmic reticulum induced by the mutant protein and an increase in β-cell apoptosis [89]. 
In the first part of my thesis, I have used the Akita mutation as a means to reduce circulating 
plasma insulin levels in the PpargP465L/+ mice to prove the hypothesis that PpargP465L/+ causes 
insulin resistance. 
Apoe-/- Mice: 
Apolipoprotein E -/- (Apoe-/-) mice are a well established model of atherosclerosis which has been 
widely used to study the pathophysiology as well as treatment modalities of this disease.  Apoe-/- 
mice have spontaneous hypercholesterolemia and hypertriglyceridemia with reduced high-density 
 
 40 
lipoprotein (HDL) levels [90].  These mice also develop spontaneous atherosclerotic lesions in 
their arteries [91].  In young mice, the lesions begin as subendothelial foam cell deposits in the 
aortic sinus close to the aortic valve area.  Over the course of time, accumulation of foam cell 
deposits and free cholesterol along with smooth muscle cell proliferation leads to the propagation 
of the atherosclerotic plaque and the lesions spread to other areas of the aorta including the arch.  
In 8-9 month old mice, complex lesions are demonstrable with well defined fibrous caps.         
In the second part of my thesis, I used Apoe-/- mice to mimic the human condition of 
atherosclerosis to study the effect of PpargP465L/+ mutation on atherosclerosis severity and to 
investigate the hypothesis that PpargP465L/+ will worsen atherosclerotic lesion size.    
Most of the scientific evidence presented above was generated in global or tissue specific knockout 
mice, which are a result of artificial manipulations occurring only in the experimental settings.  
Thus, it is important to study PPARγ in a context which is possible in human patients.  I chose the 
P465L mutation in mouse PPARγ since the original mutation (P467L) was identified in human 
patients.  Although the mutation itself is a very rare event, it can be considered as a representative 
of several mutations identified in the ligand binding domain of PPARγ.  This study has enabled me 
to understand the effects of reduction in the level of normal PPARγ protein and the presence of an 
altered protein on adipose tissue physiology, insulin sensitivity and atherosclerosis.  These results 
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C h a p t e r  2  
OVERALL GOAL AND HYPOTHESIS 
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The overall goal of this dissertation is to study the effect of a dominant negative point mutation in 
Peroxisome Proliferator Activated Receptor γ (PPARγ), PPARγP465L/+, on insulin sensitivity and 
atherosclerosis. 
PPARγ is a ligand-activated transcription factor that belongs to the family of nuclear hormone 
receptors.  It is necessary and sufficient for adipose tissue differentiation and triglyceride 
accumulation in adipocytes.  Thiazolidinediones (TZDs), which are the synthetic ligands of 
PPARγ, are used as insulin sensitizers to treat millions of pre-diabetic and diabetic patients.  The 
insulin-sensitizing actions of PPARγ are complex, brought about via multiple organs, and are less 
well characterized than its role in adipocyte differentiation.  PPARγ is also shown to play a role in 
blood pressure regulation and TZDs have been shown to reduce blood pressure in both diabetic and 
non-diabetic human patients.  In addition, PPARγ is also known to affect macrophage 
differentiation and lipid uptake. 
Insulin resistance and hypertension often co-exist and independently and jointly contribute to 
worsen the outcome of cardiovascular disease.  This prompted me to investigate the role of 
PPARγP467L/+ mutation in these two patho-physiological conditions, both of which are known to be 
modulated by PPARγ.  The PPARγP467L/+ mutation was originally identified in human patients who 
have severe hyperglycemia and insulin resistance.  These patients also have early onset 
hypertension and lipodystrophy.  Mice with the corresponding PpargP465L/+ mutation recapitulate 
the phenotype of hypertension and lipodystrophy, but are not insulin resistant.  They have normal 
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plasma glucose levels and a small increase in plasma insulin which is exacerbated by high fat diet.  
Since this mutation was identified by screening hyperglycemic patients with insulin resistance, it is 
possible that the mutation is merely associated with insulin resistance and part of my work is 
focused on ruling out this possibility.  Thus, the first part of my thesis is an attempt to understand 
whether the PpargP465L/+ (L/+) mutation in the ligand binding domain of PPARγ, can cause insulin 
resistance.   
I hypothesized that the increase in plasma insulin found in P465L/+ mice compensates for the 
insulin resistance caused by this mutation and acts to maintain normal plasma glucose levels.  To 
test this hypothesis, I used Ins2Akita/+ or Ins2C96Y/+ mice.  The Ins2Akita/+ mutation leads to a reduction 
in circulating insulin levels.  Mice carrying this mutation would not have the extra insulin required 
to maintain normal plasma glucose levels in P465L/+ mice and would potentially uncover the 
insulin resistance phenotype in the carriers of the P465L/+ mutation.  Unlike Ins2Akita/+ littermates, 
male PpargP465L/+Ins2Akita/+mice have drastically reduced life-span and enhanced Type I diabetes.  
Hyperglycemia in Ins2Akita/+ females is mild.  However, PpargP465L/+Ins2Akita/+ females have 
aggravated hyperglycemia, smaller insulin-producing pancreatic islets and reduced plasma insulin.  
In an insulin tolerance test, they showed smaller reduction in plasma glucose indicating impaired 
insulin sensitivity.  While gluoconeogenesis is enhanced in PpargP465L/+Ins2Akita/+ female mice 
compared to Ins2Akita/+, exogenous insulin equally suppressed gluconeogenesis in primary 
hepatocytes obtained from these mice, suggesting that PpargP465L/+Ins2Akita/+ livers are insulin 
sensitive.  Comparable expression of genes regulating insulin sensitivity, and glycogen and 
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triglyceride contents suggest that skeletal muscles are equally insulin sensitive.  In contrast, 
adipose tissue and isolated adipocytes from PpargP465L/+Ins2Akita/+ mice have impaired glucose 
uptake in response to exogenous insulin.  In addition, PpargP465L/+Ins2Akita/+ female mice have 
smaller fat depots composed of larger adipocytes suggesting impaired lipid storage with 
subsequent hepatomegaly and hypertriglyceridemia.  
PPARγ in endothelium, vascular smooth muscle cell and macrophage is shown to beneficially 
modulate blood pressure, cellular adhesion and migration and vasoconstriction.  In the second part 
of my thesis, I have tested the hypothesis that increased blood pressure and reduced or altered 
activity of PPARγ due to the presence of P465L/+ mutation increase atherosclerosis plaques.  To 
test this hypothesis we used mice that are deficient in apolipoprotein E (Apoe-/-), which have 
hypercholesterolemia and spontaneously develop atherosclerotic lesions.  ApoE is involved in 
ligand-dependant clearing of lipids from the plasma and is crucial to maintain normal levels of 
plasma lipids.   
Surprisingly, we did not see an increase in atherosclerotic plaque size in the double mutant mice 
(Lee) carrying P465L/+ mutation on the apoE null background.  The Lee mice had higher blood 
pressure levels, which can potentially increase atherosclerotic plaque size.  As expected, Lee mice 
had decreased expression of scavenger receptor CD-36 in macrophages.  However, unlike Pparg-/- 
macrophages, Lee mice had an increase in Abca-1 expression, suggesting increased cholesterol 
efflux.  Lee mice had a protective phenotype in the macrophages where VLDL uptake was 
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significantly reduced compared to Apoe-/- control mice, suggesting a reduced formation of foam 
cells in the Lee mice.  It is likely that the increase in blood pressure with its pro-atherogenic 
potential and the athero-protective phenotype in the macrophage balance each other, resulting in an 
unchanged plaque.   
Chapter 1 gave a detailed scientific background for my study.  I describe the structure and 
mechanism of action of PPARγ followed by the functional role of PPARγ in adipogenesis, blood 
pressure regulation, macrophage lipid uptake and atherosclerosis.  I describe the phenotype of 
P465L/+ mutation and discuss in detail the choice and characteristics of the other two mouse 
models (Ins2Akita/+ and ApoE-/-) used to test my hypotheses.  In the next chapters, I will discuss the 
scientific background on which these studies are based, including a detailed description of the 
mouse models used, the results, and my interpretation and conclusions based on these data.   
 
Chapter 3 discusses the findings from my first hypothesis that PpargP465L/+ mutation may cause 
insulin resistance.  Utilizing the Ins2Akita/+ mouse, I showed that adipose tissue with its dependence 
on PPARγ and insulin early in its development, is structurally and functionally affected by the 




Akita/+ (LA) mice.  Liver and skeletal muscles are relatively spared by this mutation.  
This chapter consists of material published in the manuscript titled “Pparg-P465L mutation 
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worsens hyperglycemia in Ins2-Akita female mice via adipose-specific insulin resistance and 
storage dysfunction” in the Diabetes journal (November, 2010).  
 
Chapter 4 consists of my findings from the Lee double mutant mice  
(PpargP465L/+; Apoe-/-)  used to test the hypothesis that the P465L/+ mutation will increase the size 
of atherosclerotic plaques.  We found that the plaque size was not changed in the presence of the 
P465L/+ mutation on normal chow, high fat diet or with Thiazolidinedione (TZD) treatment.  The 
plaques increased in size when the mice were made diabetic with streptozotocin (STZ) treatment, 
however there was no genotype difference.  In this chapter, I also discuss the phenotype of 
macrophages obtained from Lee mice and the possibility that hypertension and a protective 
macrophage phenotype may counteract to explain the absence of an increase in the atherosclerotic 
plaque. 
 
Chapter 5.  Similar to the multifaceted role of PPARγ in adiposity, glucose and lipid homeostasis 
and blood pressure regulation, apoE is also emerging as a crucial molecule at the cross roads of 
lipid and glucose metabolism.  We discuss the role of apoE in modulating atherosclerosis and 
metabolic syndrome and look at the contribution of the three human apoE isoforms.  This chapter 
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consists of published material from a review article titled “ApoE Knock-out and Knock-in Mice: 
Atherosclerosis, Metabolic Syndrome, and Beyond” in the Journal of Lipid Research.   
 
Chapter 6 consists of the overall conclusions of my experiments conducted to prove the two 








C h a p t e r  3  
PPARG-P465L MUTATION WORSENS HYPERGLYCEMIA IN INS2-AKITA FEMALE 
MICE VIA ADIPOSE-SPECIFIC INSULIN RESISTANCE AND STORAGE 
DYSFUNCTION. 
(This chapter consists of material from a manuscript reprinted with permission from Diabetes; 
2010 Nov;59(11):2890-7. Epub 2010 Aug 19; titled “Pparg-P465L mutation worsens 
hyperglycemia in Ins2-Akita female mice via adipose-specific insulin resistance and storage 




The dominant-negative P467L mutation in peroxisome proliferator activated receptor-γ (PPARγ) 
was identified in insulin resistant patients with hyperglycemia and lipodystrophy.  In contrast, mice 
carrying the corresponding Pparg-P465L mutation have normal insulin sensitivity, with mild 
hyperinsulinemia.  We hypothesized that murine Pparg-P465L mutation leads to covert insulin 
resistance, which is masked by hyperinsulinemia and increased pancreatic islet mass, to retain 
normal plasma glucose.  We introduced in PpargP465L/+ mice an Ins2-Akita mutation that causes 
improper protein folding and islet apoptosis to lower plasma insulin.  Unlike Ins2Akita/+ littermates, 
male PpargP465L/+Ins2Akita/+mice have drastically reduced life-span with enhanced Type I diabetes.  
Hyperglycemia in Ins2Akita/+ females is mild.  However, PpargP465L/+Ins2Akita/+ females have 
aggravated hyperglycemia, smaller islets and reduced plasma insulin.  In an insulin tolerance test, 
they showed smaller reduction in plasma glucose indicating impaired insulin sensitivity.  While 
gluoconeogenesis is enhanced in PpargP465L/+Ins2Akita/+ female mice compared to 
Ins2
Akita/+littermates, exogenous insulin equally suppressed gluconeogenesis in primary 
hepatocytes isolated from these mice, suggesting that PpargP465L/+Ins2Akita/+ livers are insulin 
sensitive.  Comparable expression of genes regulating insulin sensitivity and glycogen and 
triglyceride contents suggest that skeletal muscles are equally insulin sensitive.  In contrast, 
adipose tissue and isolated adipocytes from PpargP465L/+Ins2Akita/+ female mice have impaired 
glucose uptake in response to exogenous insulin.  In addition, PpargP465L/+Ins2Akita/+ mice have 
smaller fat depots composed of larger adipocytes suggesting impaired lipid storage with 
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subsequent hepatomegaly and hypertriglyceridemia.  PPARg-P465L mutation worsens 
hyperglycemia in Ins2Akita/+ mice primarily due to adipose-specific insulin resistance and altered 
storage function.  This underscores the important interplay between insulin and PPARγ in adipose 
tissues in diabetes.  
3.2 Introduction 
Diabetes mellitus is a major health care challenge in itself and significantly increases 
cardiovascular disease morbidity and mortality. As a multi-factorial, chronic disease, diabetes 
emanates from the complex interaction of genetic and environmental influences.  Among the many 
factors presumed or shown to contribute to its pathology, peroxisome proliferator activated 
receptor-γ (PPARγ) is an important candidate.  PPARγ is a nuclear receptor, and is necessary for 
adipocyte differentiation and triglyceride deposition [1].  Activation of PPARγ has already 
provided therapeutic potential.  One group of its synthetic ligands, the thiazolidinedione drugs, has 
found applications as anti-diabetic agents with insulin-sensitizing actions [2].   
 
Various point mutations in PPARγ that affect adipose tissue distribution and insulin sensitivity 
have been identified in humans.  For example, the PPARG-P12A polymorphism in humans is 
associated with reduced body weight and increased insulin sensitivity [3].  Increased PPARγ 
activity in PPARG-P115Q mutation is associated with severe obesity and mild insulin resistance 
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[4].  Conversely, two dominant negative mutations resulting in decreased PPARγ activity, 
PPARG-P467L and PPARG-V290M, were reported in patients with severe insulin resistance [5].  
To date, various mouse models have demonstrated the role of PPARγ in varied metabolic 
processes.  Lack of Pparg causes embryonic lethality in mice [6,7] and the Pparg-null embryos 
have no perceptible adipose tissue [6,8].  Tissue specific Pparg knockouts in liver [9] and skeletal 
muscle [10] exhibit insulin resistance.  In contrast, absence of Pparg in beta cells does not affect 
glucose homeostasis, although it increases β cell mass [11].  Animals entirely lacking Pparg are 
non-viable and tissue-specific knockouts offer a strategy for artificial manipulation which is only 
possible within experimental settings.  Thus, an important step is to extend this work to study the 
role of PPARγ in a context applicable to human patients.   
 
The dominant-negative heterozygous PPARG-P467L mutation was originally identified in patients 
with severe insulin resistance, hyperglycemia, lipodystrophy and hypertension [5].  Mice carrying 
the corresponding Pparg-P465L mutation (L/+ or L) recapitulate the hypertension and altered fat 
distribution phenotype (Tsai).  However, L/+ mice exhibit normal plasma glucose and insulin 
sensitivity [12,13].  These mice have mild hyperinsulinemia and increased pancreatic islet mass, 
especially on high-fat diet [12].  In this study, we attempted to understand whether the observed 
insulin resistance phenotype in human patients is indeed attributable to L/+ mutation or a mere 
association.  We hypothesized that mice carrying the L/+ mutation have covert insulin resistance; 
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however the simultaneous occurrence of islet hyperplasia and hyperinsulinemia compensates for 
this insulin resistance to retain normal plasma glucose.   
Improper folding of insulin due to the C96Y Ins2Akita/+ mutation causes endoplasmic reticulum 
stress and β-cell apoptosis leading to reduced plasma insulin [14].  The Ins2Akita/+ mutation only 
affects the β-cells in the pancreatic islets and the heterozygous Akita mice develop consistently 
elevated plasma glucose levels early in post-natal life.   Consequently, Akita model is uniquely 
suited to test our prediction that with reduced insulin production, the PpargP465L/+ mice would be 
unable to compensate for the peripheral insulin resistance.  We here show that the Akita females 
with PpargP465L/+ mutation have increased severity of hyperglycemia and insulin resistance 






double mutant mice:  Heterozygous male PpargP465L/+ mice on 
129/SvEvTac background [12] were mated with heterozygous female Ins2Akita/+ mice on C57BL/6J 




Akita/+ (LA), Pparg+/+ Ins2Akita/+(WA), PpargP465L/+Ins2+/+ (L+) and  wild type 
(W+).  At 3 and 7 months of age, mice were fasted for four hours for characterization of 
hyperglycemia and to define the organ specific phenotype respectively.  Mice were fed regular 
chow (LabDiet 5P76; PMI Nutrition International) and were handled with Institutional Animal 
Care and Use Committees approved procedures.  Primers used for L/+ genotyping were CAC-
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GAA-TCA-CCA-GCA-ACA-TG and CCC-ATT-CTT-GTC-ATG-ATT-CCC.  Primers used for 
Akita genotyping were CTG-ATG-CCC-TGG-CCT-GCT and TGG-TCC-CAC-ATA-TGC-ACA-
TG. 
 
Biochemical determinations:   Plasma concentrations of glucose, cholesterol, non-esterified free 
fatty acids (NEFA) and 3-Hydroxybutyrate (3-HB) were determined by kits from Wako 
(Richmond, VA, USA).  Triglyceride (TG) concentrations were determined using kits from 
Stanbio (San Antonio, TX, USA).  Plasma insulin and leptin were determined by ELISA (Crystal 
Chem Inc., Chicago, IL, USA).  Pooled plasma samples (100 µl) were fractionated by fast protein 
liquid chromatography using Superose 6 HR10/30 column (GE Healthcare, Piscataway, NJ, USA).  
Plasma adiponectin was measured by an ELISA using murine adiponectin specific antibody 
(Sigma, St Louis, MO, USA).  Tissue glycogen content was determined as difference of glucose 
contents before and after digestion with aspergillus niger amyloglycosidase (Sigma #046K8801) as 
described [15].  
 
Oral Glucose Tolerance Test (OGTT):  After 4 hour fast, 7 month old female mice were 
administered 1.3 mg/g body weight of D-glucose (Columbus Chemical Industries Inc, Columbus, 
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Wisconsin, USA) by oral gavage.  Blood was collected before and at indicated times after glucose 
administration to determine plasma glucose.  
 
Intraperitoneal Insulin Tolerance Test (IPITT):  After 4 hour fast, 7 month old female mice 
were injected intraperitoneally with insulin (Novolin; 0.5 U/kg body weight; Novo Nordisk Inc, 
Princeton, NJ, USA).  Blood was collected before and at indicated times after insulin injections to 
determine plasma glucose and NEFA.  
 
Insulin Stimulated Glucose Uptake in Adipose Tissue:  Inguinal and gonadal adipose tissues 
from 2 female mice from each genotype were cut into small pieces (20–40 mg) under aseptic 
conditions and incubated in high glucose Dulbecco's modified Eagle's medium supplemented with 
100 IU/ml penicillin and 100 µg/ml streptomycin (Sigma-Aldrich, St Louis, Missouri, USA) in the 
absence or presence of 100 nM insulin (Insulin solution from Bovine Pancreas; Sigma-Aldrich 
Inc).  After 24 hours, glucose reduction in the medium was measured and results normalized to 




Gene expression:   Total RNA was purified using Automated Nucleic Acid Workstation ABI 
6700, and real-time PCR was performed in ABI PRISM 7700 Sequence Detector (Applied 
Biosystems).  β-Actin mRNA was used for normalization.  Primers and probes are available on 
request (Table #3.3). 
 
Morphological analysis:  Paraffin sections from adipose tissue and pancreas of female mice (n ≥ 
4) were stained with H&E.  Adipocyte size was measured in ~250 cells per mouse using ImageJ 
software.  Mean pancreatic islet area, the average from all islets identified on each section, was 
determined.  
 
Pyruvate Tolerance Test (PTT):  After 14 hour fast, 3 month old female mice were injected 
intraperitoneally with 2 mg/kg body weight of sodium pyruvate (Sigma, St. Louis, Missouri, 
USA).  Blood was collected before and at indicated times after injection to determine plasma 
glucose.  
 
Glucose production from primary hepatocytes:  Primary hepatocytes were isolated as described 
[18] and plated on mouse-collagen IV coated plates.  Cells were washed twice with PBS to remove 
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glucose and incubated for 16 hours in 500µl medium containing 10nM dexamethasone, 0.5mM 
IBMX with and without 2mM sodium pyruvate and 100nM insulin.  Glucose concentration was 
measured in 100µl medium.  
 
2-deoxy-glucose uptake:  Hepatocytes were plated at 100,000 cells per well in a 24-well plate and 
maintained in a hepatocyte culture medium (Xenotech, Lenexa, Kansas U.S.A.) for 24 hours.  The 
cells were washed with PBS and maintained in serum free medium containing 135mM NaCl, 
5.4mM KCl, 1.4 mM CaCl2, 1.4mM MgSO4 and 10mMNa4P2O7 for 30 minutes [19].  2-deoxy-
D[1-3H]glucose (Perkin-elmer) was added to a final concentration of 1 µCi/ml, and cells were 
incubated for 10 min [20].  Cells were washed three times with PBS and solubilized in 1 ml 1% 
SDS. Radioactivity in 350µl aliquots was measured in a scintillation counter.  Glucose uptake was 
normalized to protein content and expressed as milligrams of glucose per gram of protein.  In a 
similar experiment, primary adipocytes were isolated and 2-deoxy-D[1-3H]glucose (Perkin-elmer) 
uptake was measured in absence or presence of 100nM insulin as previously described [21,22]. 
 
Data analysis:  Values are reported as mean±SEM.  Statistical analyses were conducted using 
two-way ANOVA with Pparg and Ins2 genotypes as two factors.  Student’s t test was used for 
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comparisons between groups, and differences were considered to be statistically significant if p< 
0.05.  
3.4 Results 
Increased hyperglycemia in Ins2
Akita/+ mice carrying the Pparg-P465L mutation.  From our 
breeding scheme, we obtained F1 mice with four genotypes: wild type (W+), PpargP465L/+(L+), 
Ins2
Akita/+(WA), and PpargP465L/+Ins2Akita/+ (LA) mice. The mice were born in the expected 
Mendelian ratio; however, all LA male mice died before 150 days demonstrating significantly 
reduced survival (Fig 3.1A).  In contrast, more than 85% WA males survived and all W+ and L+ 
males survived to this age.  Younger LA males at 6 weeks of age had higher fasting plasma 
glucose (LA 577±31 and WA; 494±40 mg/dl, n = 6, Fig 1B) and triglyceride (TG) compared to 
WA mice, although these increases did not reach significance (Figure 3.2A).  However, LA males 
had significantly higher fasting plasma ketone body levels (LA; 407± 23 and WA; 271±40 µmol/L, 












Figure 3.1: Increased hyperglycemia in Ins2
Akita/+ mice carrying the PPARγP465L/+ mutation.  (A) 
Reduced survival in male LA (n=12, solid line) mice compared to WA (n=12, dashed line) 
littermates. (B) Fasting plasma glucose in 6 week old male LA mice (n=10, black bars) compared to 
male WA littermates (n=12, white bars). (C) Fasting plasma ketone body (3-HB) levels in 6 week old 
male LA mice (n=4) compared to male WA littermates (n=6). (D,E) Fasting plasma glucose and 
triglyceride levels in female LA (black bars) and WA (white bars) littermates at 3 and 7 months of 
age (n≥6).  (F) Fasting plasma ketone bodies in 3 month old female LA (n=6) and WA (n=7) 
littermates. * p< 0.05, ** p< 0.01.  
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In contrast to LA males, LA females demonstrated normal survival throughout 7 months of the study 
period.  We therefore focused on WA and LA females to understand the effects of Pparg-P465L mutation 
on peripheral insulin sensitivity and diabetes severity.  Basic characterization of a set of 3 month old mice 
is shown in Table 3.1.   
The LA double mutant female mice had significantly higher fasting plasma glucose compared to 
WA littermate control females.  This increase in plasma glucose was apparent at 3 months of age 
(LA; 508±23, n=6 vs WA; 354±36 mg/dl, n=13; p< 0.01) and compared to glucose levels in a wild 
type mouse (~120 mg/dl), hyperglycemia persisted throughout the study period of ~7 months (LA; 
369±38, n=6 vs WA; 273±24 mg/dl, n=13; p< 0.05 Fig 3.1D).  The LA female mice had 
significantly high fasting plasma TG levels at both 3 months and 7 months of age (LA; 78±12 and 
65±6, WA; 51±3 and 45±3 mg/dl, n=6; p< 0.01 Fig 3.1E).  As expected in a diabetic state, this 
increase in plasma triglyceride level was mainly due to an increase in the very low density 
lipoproteins (Figure 3.2).  Diabetes, with its low levels of functional insulin, is the most common 
pathological cause of elevated ketone bodies [23].  Consistently, LA females had significantly 
higher levels of 3-hydroxybutyrate compared to WA mice after 4 hours of fasting (LA, 395±63, 




 +/+;+/+ L/+;+/+ +/+;A/+   
(WA) 




178±37  (11) 171±23     
(10) 
354±36       
(13) 




40±4 38±2 51±12 78±12 
Body weight 
(grams) 
23.05±1.14  23.34±0.72  23.41±0.81   22.25±0.8    
Food Intake 
(gm/d) 
3.0±0.8 3.8±0.3 3.13±2.3 3.43±0.3 
Water Intake 
(ml/d) 
4.0±1.3 3.4±0.3 5.9±2.9 7.9±2 
Urine Output 
(ml/d) 
1.3±0.3 1.45±0.2 3.78±2.7 4.84±1.5 
Liver/BW (%) 3.64±0.3     4.03±0.17    4.08±0.19     4.27±0.2     
Gonadal 
Fat/BW (%) 
1.17±0.13 0.89±0.07 1.24±0.19 0.67±0.07 
Inguinal 
Fat/BW (%) 
1.0±0.05 1.2±0.09 0.87±0.08 0.88±0.07 
Total Fat/BW 
(%) 
0.56±0.08    0.54±0.05   0.56±0.06    0.4±0.06      
Systolic BP 
(mmHg) 
102.3±2        n.d. 104±3          112±2.5*           
Liver Glycogen 
(/gram protein) 
0.23±0.06  0.14±0.03  0.19±0.3      0.18±0.03    
Liver TG 
(/gram protein) 
0.14±0.02   0.16±0.01    0.13±0.01     0.12±0.01    
 



































Figure3.2: Plasma lipids and islets in female WA and LA mice. (A) Fasting plasma 
triglyceride in male LA (n=10, white bars) tended to be higher in male WA (n=12, 
black bars) littermates.  (B) Triglyceride distribution in plasma lipoproteins of 3 
month old females fractionated by the fast protein liquid chromatography.  LA 
females (solid line) had increased triglycerides in the very low fractions (fractions 
13-15).  (C,D) Typical pancreatic islet histology in WA(C) and LA(D)  mice.  The 
sections were stained with hematoxylin and eosin.  Original magnification 10x. 
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We next performed an oral glucose tolerance test, where LA females had significantly higher 
plasma glucose levels at various time points up to 2 hours after administration of glucose load (Fig 
3.3A).  Fifteen minutes after glucose challenge, the LA female mice had significantly lower plasma 
insulin levels compared to WA mice (LA, 0.36±0.01, n=4 and WA, 0.49±0.03 ng/ml, n=6; p= 
0.01, Fig 3.3B).  This lower glucose-stimulated insulin level in LA mice was accompanied by 
significantly smaller mean pancreatic islet area when compared to age matched WA controls (Fig 
3.3C and Figures 3.2C and D).   
Thus, the Pparg-P465L mutation worsens the hyperglycemia caused by Ins2-Akita mutation partly 




Figure 3.3: Reduced circulating insulin contributes to hyperglycemia in 
female LA mice. (A) Plasma glucose levels after oral glucose load and (B) 
Plasma insulin levels at 15 minutes after oral glucose administration in 
female LA mice (n=5) compared to female WA littermates (n=5). (C) 
Mean pancreatic islet area in female W+ (n=4), L+ (n=4), LA mice (n=5) 
and WA littermates (n=6).  * P< 0.05, ** P< 0.01.  Dashed line and white 
bars indicate WA, solid line and black bars indicate LA, W+ are speckled 
bars, L+ are checkered bars. 
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Adipose Tissue dysfunction contributes to Insulin Resistance in the LA females:  To test the 
hypothesis that P465L/+ mutation may cause insulin resistance in mice, we investigated whether 
insulin resistance contributes to higher plasma glucose levels in female LA mice.  In an 
intraperitoneal insulin tolerance test (IPITT), plasma glucose in WA females dropped to 70±6 % 
compared to baseline at 15 minutes after an intraperitoneal insulin injection.  However, in LA 
females the glucose levels reduced only to 94±4 % (n=6, p< 0.01, Fig 3.4A).  Thus, insulin-
mediated suppression of plasma glucose was impaired in LA females.    In addition to glucose 
homeostasis, insulin also suppresses non-esterified fatty acis (NEFA) release, largely from the 
adipose tissue [24].  WA and LA mice have a large difference in their baseline glucose levels, but 
have comparable fasting NEFA levels.  I therefore examined NEFA as an additional parameter to 
measure the insulin sensitivity in LA mice.  In IPITT, NEFA levels in LA mice were significantly 
higher than WA controls 15 minutes after insulin injection (LA 0.65±0.04, n=5 and WA, 
0.51±0.02 mEq/L, n=6; p< 0.01, Fig 3.4B).  This suggests that LA mice were not able to suppress 
the NEFA release as effectively as the WA controls.  PPARγ is widely recognized as an important 
regulator of adipose tissue differentiation.  Mice carrying the Pparg-P465L mutation have normal 
total adipose tissue mass with altered fat distribution [12].  Insulin is also known to be an important 
player in adipose tissue physiology.  LA mice carrying mutations in both these important genes 
have a significant reduction in their total adipose tissue mass and have lower body weight (Fig 
3.4C, F).  They have reduced gonadal (visceral) adipose tissue (similar to L+ mice) but a slight 
reduction in inguinal (subcutaneous) adipose tissue (unlike L+ mice, which have a significantly 
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higher inguinal fat mass than W+ mice) (Table 3.1).  Thus, simultaneous presence of Pparg-P465L 
and Ins2-Akita mutations severely compromises the normal adipose tissue development.   
Median size of individual adipocytes from the inguinal depot was significantly larger in the LA 
mice than those in the WA mice (Figure 3.5) and an assessment of gonadal adipocytes suggested a 
similar change.   Presence of larger cells in a smaller fat depot suggests that the adipose tissue in 














Figure 3.4: Insulin resistance in adipose tissue of LA female mice. (A) Blunted fall in plasma 
glucose and (B) suppression of NEFA secretion in LA mice (n=5, solid line) compared to WA 
littermates (n=6, dotted line) in response to intraperitoneally administered insulin 0.5U/Kg 
body weight. (C) Adipose tissue weight normalized with body weight of 3 mo old female LA 
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(n=7, black bars) and WA mice (n=7, white bars) GF, perigonadal fat; IF, inguinal fat; BF, 
brown fat and TF, total fat. (D) Plasma adiponectin and (E) leptin and (F) body weight in LA 
(n=6) and WA mice (n=7).  Glucose uptake in primary adipocytes (G) and adipose tissue 




Figure 3.5: Adipocyte size distribution: Size distribution of the adipocytes in the inguinal 
depots indicates larger adipocytes in female LA mice (solid line) compared to WA littermates 
(dashed line).  Individual cell areas are measured in ~250 cells in paraffin sections of each of 
the 4 mice per genotype.   
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The LA mice also had significantly reduced plasma levels of adiponectin (LA; 24.4±1.5, n=3 vs. 
WA; 42.5±6.2 µg/ml, n=3; p< 0.05, Fig 3.4D) and leptin (LA; 0.8±0.1, n=8 vs. WA; 2.3±0.5 
ng/ml, n=8; p< 0.05, Fig 3.4E).  Adiponectin and leptin are primarily produced in adipose tissue 
and are critical to maintain insulin sensitivity [25,26].  To understand whether reduced amount of 
adipose tissue and impaired adipokines production extends to impairment in insulin sensitivity, I 
studied primary adipocytes and adipose tissue explants in-vitro.  When mature adipocytes were 
isolated and treated with 100nM insulin, LA adipocytes had much reduced insulin-stimulated 2-
deoxyglucose uptake compared to WA adipocytes (LA; 11.92±1.4nM vs. WA; 22.11±3.23, p< 
0.05, Fig 3.4G).  The basal glucose uptake in the absence of insulin was similar in primary 
adipocytes obtained from the two genotyopes.  Similarly, glucose uptake in adipose tissue explants 
from WA mice significantly increased upon insulin stimulation.  However, glucose uptake in LA 
explants did not respond to insulin (LA; 5.3±0.5 vs. WA; 9.8±0.6 arbitrary units, p= 0.0001, Fig 
3.4H).  Again, the glucose uptake in the absence of insulin was comparable in the adipose tissue 
explants from WA and LA female mice.  This failure to increase glucose uptake in response to 
insulin by the primary LA adipocytes and LA explants demonstrate the insulin resistance 
phenotype in the LA adipose tissue.  In separate experiments, both W+ and L+ adipose tissue 
explants had similar basal glucose uptake and comparable increases in insulin stimulated glucose 
uptake confirming their normal insulin sensitivity (data not shown).     
Metabolic signaling of insulin is mediated by a phosphorylation of a cytoplasmic protein AKT 
(also known as protein kinase B), a serine/threonine kinase (Ueki, JBC, 1998).  We investigated 
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the phophorylation of AKT as a marker of insulin sensitivity.  Incubation with insulin induced a 
two fold increase in phosphorylation of AKT in primary adipocytes from inguinal and gonadal fat 
of WA mice. In contrast, insulin stimulated phosphorylation of AKT was significantly blunted in 
both inguinal and gonadal adipocytes and was not different from the un-stimulated cells from LA 
mice (Fig 3.7A,B).  The total amount of AKT protein was comparable in the two genotypes.  Thus, 
LA female mice have smaller and less functional adipose tissue which contributes to the mild 
insulin resistance phenotype as observed by IPITT in these mice.     
Increased gluconeogenesis contributes to fasting hyperglycemia in LA mice:  In a fasted state, 
liver maintains the plasma glucose at a certain level by glycogenolysis and gluconeogenesis.  This 
glucose generated in the liver is available to tissues such as brain to utilize as an energy source.  As 
LA female mice have significantly high fasting plasma glucose levels, I next studied the 
contribution of the liver to this phenotype.  LA livers revealed a 2.2 fold reduced expression of 
glucokinase (GK), a key glucose uptake enzyme, compared to WA mice (p= 0.06, Fig 3.6A).  
Analysis with two way ANOVA suggests that both Pparg genotype (p< 0.05) and Ins2 genotype 
(p< 0.05) have significant effects and additively contributing to the reduced glucokinase expression 
in LA mice. I observed a 2 fold reduction in the gene expression of sterol regulatory element 
binding protein (SREBP-1) which binds to and increases the transcription of glucokinase gene (p< 
0.05).  Consistent with the gene expression profile, the uptake of 2-deoxyglucose was significantly 
lower in primary hepatocytes isolated from LA compared to WA females (WA; 4.29±0.7 and LA; 
1.51±0.28 mg/g protein, p<0.01, Fig 3.6B).  In contrast to genes for glucose uptake, there was a 
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significant 1.5 fold increase in the gene expression for phosphoenolpyruvate carboxykinase 




Figure 3.6: Altered liver function due to reduced plasma insulin levels contributes to 
increased hyperglycemia in LA mice.  (A) Average mRNA amounts of genes for GK, 
SREBP-1 and PEPCK in L+ (checkered) WA (white) and LA (black) mice relative to that in 
W+ mice (speckled) as 1.0 (n≥ 7).  (B) Uptake of 2-deoxy-glucose in primary hepatocytes. (C) 
Increase in plasma glucose after an intra-peritoneal administration of 2 mg/Kg body weight 
pyruvate in LA female mice compared to WA littermates (n=4 each).  (D) Glucose 
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production (mg/gram protein) in cultured WA (white bars) and LA (black bars) hepatocytes.  
Increase in glucose in the medium by the addition of 2mM Sodium pyruvate was suppressed 
by the presence of 100nM insulin. (E) Increased liver weight and (F) a small increase in liver 




We next performed a pyruvate tolerance test to assess the rate of gluconeogenesis in WA and LA 
female mice.  LA mice indeed demonstrated a 2.3 fold greater increase in plasma glucose levels 
compared to WA mice at 60 minutes after an intraperitoneal injection of pyruvate (p< 0.05, Fig 
3.6C).  Thus, impairment in glucose uptake combined with increased hepatic glucose production 
contributes to the fasting hyperglycemia in LA females compared to WA controls.  Corroborating 
with the in vivo data, glucose production from primary hepatocytes, isolated from LA mice, 
increased significantly in the presence of pyruvate (2.7 fold) compared to 1.3 fold in WA 
hepatocytes.  (The upregulated gluconeogenesis can be due to a deficiency of circulating insulin or 
a resistance to insulin described earlier in the LA mice.)  This increase in gluconeogenesis was 
completely suppressed in the presence of exogenous insulin in both genotypes (Fig 3.6D).  
Furthermore, the Akt phosphorylation in hepatocytes from both WA and LA mice was increased 
comparably after incubation with 100nM insulin for 10 minutes (Fig 3.7C).  Thus, hepatocytes 
from LA mice are as sensitive to exogenous insulin as WA cells.  
At 7 months, the LA female mice also had a small yet significant increase in their liver weight (LA 
4.68±0.14 n=6, and WA 3.9±0.08%, n=12, p< 0.05, Fig 3.6E).  This increase is partially explained 
by a small increase in liver triglyceride content per gram of protein (Fig 3.6F).  Since the liver 
weight and triglyceride accumulation was not different in LA and WA female mice at 3 months 











Figure 3.7:  Akt phosphorylation status.  Western blot for pAKT (upper panels), total AKT 
(middle panels) and β-actin (lower panels) in adipocytes isolated from inguinal fat (A), 
gonadal fat (B) and hepatocytes (C).  Cells were incubated with 100nM (+) or without (-) 
insulin for 10 minutes.  Antibodies used were phsopho-Akt (Thr308) (Cell Signaling #2965), 
Akt (Cell Signaling #9272) and β-actin (Cell Signaling # 5125). 
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PpargP465L mutation does not affect glucose handling and insulin sensitivity in the skeletal 
muscle.  The mRNA level of Glut-4, the major insulin-sensitive glucose transporter in skeletal 
muscle, showed no change in LA mice compared to WA mice.  Expression levels of AdipoR1, IR, 
and IRS-1, genes important for normal insulin sensitivity were also unchanged (Fig 3.8A and table 
3.2).   
Insulin resistance is usually associated with increased intracellular accumulation of lipids [27]; 
however, the skeletal muscle triglyceride levels were unaltered by the presence of Pparg-P465L 
mutation (Fig 3.8B).  Glycogen content was increased in mice with the Akita mutation but Pparg-
P465L mutation had no effects (Fig 3.8C).  Taken together, these data indicate that glucose 
handling and insulin sensitivity in skeletal muscle are largely unaffected by Pparg-P465L 




Figure 3.8: Normal glucose handling in skeletal muscle.  (A) Gene expression of Glut4, 
AdipoR1, IR and IRS-1 in female WA (white bars) and LA (black bars) mice.  Data are 
expressed as mean±SE relative to the mean level in wild type animals set as 1.0.  (B)  
Triglyceride content per gram of protein in skeletal muscle in female mice.  (C)  Skeletal 




 W+ L+ WA LA 
Liver     
PPARγ 1.0±0.26 0.92±0.16 1.11±0.22 1.15±0.21 
PPARα 1.0±0.08 1.39±0.37 1.02±0.1 1.13±0.15 
PGC-1α 1.0±0.3 0.77±0.39 1.1±0.18 1.15±0.32 
IR 1.0±0.16 1.02±0.23 1.13±0.18 1.15±0.32 
IRS-1 1.0±0.7 0.28±0.04 0.41±0.08 0.27±0.05 
AdipoR2 1.0±0.37 0.7±0.2 0.97±0.16 1.3±0.6 
Skeletal Muscle     
PPARγ 1.0±0.06 0.61±0.03 1.38±0.05 1.23±0.04 
PPARα 1.0±0.05 0.65±0.05 0.74±0.03 1.07±0.08 
IR 1.0±0.08 1.08±0.13 0.7±0.06 0.87±0.07 
IRS-1 1.0±0.08 1.8±0.33 1.11±0.3 1.01±0.09 
Glut-4 1.0±0.76 0.84±0.6 0.2±0.08 0.17±0.08 
AdipoR1 1.0±0.46 1.41±1.1 0.86±0.4 0.78±0.7 
Table 3.2: Gene expression data from 3 month old female mice.   n≥4 for all genotypes, 




Glucose tolerance and insulin resistance are complex phenomena affected by multiple signaling 
mechanisms in varied organs.  For an individual as a whole, the implications of being 
hyperglycemic and insulin resistant are serious.  In this study we focused on a dominant negative 
point mutation, Pparg-P465L, in the ligand binding domain of PPARγ and established that this 
mutation can worsen the hyperglycemia caused by the diabetogenic Ins2-Akita mutation.  The 
higher plasma glucose in female LA mice compared to WA females can be accounted for by 
adipose tissue-specific insulin resistance, reduced circulating plasma insulin and increased hepatic 
gluconeogenesis.   
 
Pparg is expressed in pancreatic islets, where it has a growth inhibitory role.  Targeted elimination 
of Pparg in β-cells led to bigger pancreatic islet mass without alterations in glucose homeostasis 
[11].  Unlike the wild type islets, Pparg deficient islets lack the ability to expand in response to 
high fat diet [11].  In contrast, mice carrying the Pparg-P465L mutation also have bigger islets, 
particularly on a high fat diet [12].  Therefore, while the Pparg-P465L mutation is unable to exert a 
normal growth inhibitory action; it does not interfere with the expansion of islets in response to 
high fat feeding.  The Akita mutation reduces the insulin secretion from the beta cells.  Initially, the 
islets in Ins2Akita/+ mice undergo hypertrophy to compensate for the falling plasma insulin levels.  
Consistently, in our current study of mice with Ins2-Akita mutation, the islets in WA female mice 
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were enlarged.  However, the LA females had significantly smaller mean islet area compared to the 
WA islets.  The LA females also had reduced plasma insulin levels 15-minutes after an oral 
glucose dose compared to the WA littermates.  Although the direct effect of the Pparg-P465L 
mutation cannot be excluded, it is likely that the increased insulin demand from the already 
stressed pancreas accelerates apoptosis of β cells initiated by the Ins2-Akita mutation and 
contributes to the augmented hyperglycemia seen in LA mice.  Consistent with our observation, 
Evans-Mollina et al in 2009 demonstrated the positive effects of PPARγ agonist Pioglitazone on 
islet function in diabetic mice as measured by higher random insulin levels and improved glucose 
stimulated insulin release [28].  These improvements were secondary to reduced endoplasmic 
reticulum stress and improved expression profile of genes involved in glucose sensing and β-cell 
differentiation.  
 
Our studies have shown that LA mice have increased fasting plasma glucose levels and an insulin 
resistance phenotype.  In fasted states, liver is the main source of plasma glucose where pyruvate, 
amino acids and glycerol are converted into glucose through gluconeogenesis. This newly 
synthesized glucose is available as energy for tissues, in particular the brain, which relies primarily 
on carbohydrate metabolism [29].  Two fold reductions in hepatic GK expression in LA mice result 
in reduced glucose uptake.  The glucokinase promoter has a peroxisome proliferator response 
element and is transcriptionally activated by PPARγ agonists [30]. Hepatic GK expression is 
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reduced in diabetic animal models with insulin deficiency [31] and insulin has been shown to be a 
major activator of GK gene transcription [31,32] through the transcription factor SREBP-1c [30].  
We in turn observed a significant decrease in SREBP-1c expression in LA compared to WA livers.  
Thus, reduced circulating insulin levels and Pparg-P465L mutation have an additive effect to 
reduce GK expression.  In addition, the upregulation of PEPCK in these mice suggests increased 
gluconeogenesis which could explain the higher fasting plasma glucose in LA mice.  A pyruvate 
tolerance test, where LA mice showed a significantly larger increase in glucose after pyruvate 
injection, and higher pyruvate stimulated glucose production in the isolated LA hepatocytes than 
WA hepatocytes in culture, confirmed this possibility.  Thus the reduced hepatocyte glucose 
uptake coupled with upregulated gluconeogenesis contributes to higher plasma glucose in LA 
compared to WA females.  Increased hepatic gluconeogenesis in LA females could possibly result 
from a deficiency in circulating insulin and/or insulin resistance.  However, LA hepatocytes are 
able to suppress glucose production from pyruvate in response to exogenous insulin, suggesting 
that the increased hepatic gluconeogenesis observed in LA mice mainly results from a deficiency 
in circulating insulin but not hepatic insulin resistance.   
 
The insulin resistance phenotype observed in the LA females primarily arises from the adipose 
tissue.  PPARγ and insulin are both widely recognized as essential genes for adipose tissue 
differentiation and lipid deposition.  Thus, we observed that Pparg-P465L mutation on Ins2-Akita 
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background significantly reduced adipose tissue mass and adipocytokine levels as measured by 
plasma leptin and adiponectin.  Reduced plasma adiponectin and leptin could contribute to whole 
body insulin resistance.  However, liver and skeletal muscle of LA mice were equally insulin 
sensitive to those of WA mice indicating that the signaling downstream of these peptides are intact.  
Possibly the extent of decrease in adiponectin and leptin is not sufficient to alter the insulin 
sensitivity in liver and muscles.  Yet, the LA mice had adipocytes significantly reduced in number 
but larger in size, which are shown to be associated with reduced insulin sensitivity [33], 
suggesting the inability of the adipose tissue to recruit new pre-adipocytes.  The higher plasma TG, 
and a slight increase in liver TG content, observed in LA females could also be a consequence of 
this impaired storage function of the  adipose tissue. Similar to our observation, Gray et al reported 
that leptin deficient ob/ob mice carrying the Pparg-P465L mutation had a significant reduction in 
adipose tissue mass and are insulin resistant [13]. The authors attributed this to an inability of the 
adipose tissue to expand in the face of increased availability of energy.  Our in vitro data using 
adipose tissue explants and primary adipocytes suggest that LA adipose tissues also have impaired 
insulin-stimulated glucose uptake, further confirming their adipose tissue dysfunction.  While our 
conclusions were derived using Akita mutation as a source of insulin deficiency, rendering Pparg-
P465L mutant mice insulin deficient by other means such as Streptozotocin treatment and/or 
treating our model with various anti-diabetic drugs may provide further insight into the phenotype.     
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Although our study was focused on Ins2Akita/+ females, the same mechanisms must be responsible 
for the increased severity of diabetes in LA males compared with WA males.  Diabetes induced by 
Ins2-Akita mutation affects males more severely than females [34] and consequently only males 
are used as models of type 1 diabetes in general.  However, our study shows that Pparg-P465L 
mutation significantly increases hyperglycemia in Akita female and advocates the use of female 
Ins2
Akita/+ mice as an excellent model to study diabetes, particularly in female specific conditions 
including polycystic ovary syndrome and gestational diabetes.  Our mice also provide a model 
where reduced insulin and insulin resistance, signatures of type 1 and type 2 diabetes respectively, 
are simultaneously present.   
In conclusion, our study showed that Pparg-P465L mutation worsens the hyperglycemia caused by 
diabetogenic Ins2-Akita mutation, and have unmasked the insulin resistance phenotype in the 
adipose tissue of mice carrying the Pparg-P465L mutation on Ins2-Akita background.  A 
simultaneous reduction of PPARγ and insulin, which are both critical in adipocyte differentiation, 
leads to limited expansion of adipose tissues in these mice.  The primary storage defect in adipose 
tissue triggers hypertriglyceridemia.  Adipose tissue insulin resistance also increases pressure on an 
already stressed pancreas, contributes to a further destruction of beta cells and reduction in 
circulating plasma insulin.  This, in turn, causes the liver to upregulate gluconeogensis resulting in 
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C h a p t e r  4  
MILD REDUCTION OF VLDL UPTAKE IN PPARGP465L/+ MACROPHAGES IS NOT 





The increasing prevalence of obesity and insulin resistance and its negative impact on the outcome 
of atherosclerotic cardiovascular disease is of major concern.  Several mouse studies have 
established the anti-atherosclerotic effects of PPARγ and of PPARγ agonists.  The PPARγP467L 
(L/+) mutation, originally identified in human patients, affect adipose tissue distribution, insulin 
sensitivity and blood pressure.  In this study, we hypothesized that the L/+ mutation that causes 
hypertension, hyperinsulinemia, partial lipodystrophy and reduced macrophage PPARγ activity 
will worsen atherosclerosis in Apoe-/- mice.  Despite a persistent increase in blood pressure and 
lipodystrophy, presence of PPARγP465L/+ mutation did not affect atherosclerotic plaque size in 
Apoe-/- mice.  Plaque sizes were also comparable in the two genotypes after TZD treatment or 
Streptozotocin-induced hyperglycemia.  Gene expression studies revealed a significant increase in 
ABCA-1 mRNA and a small decrease in CD-36 mRNA in Apoe-/- macrophages with L/+ mutation 
compared to littermates.  Consistent with this observation, cultured Apoe-/- macrophages with L/+ 
mutation, had a small yet significant reduction in DiI-labeled-VLDL uptake from the media by 
~11%, compared to Apoe-/- macrophages.    Transfer of bone marrow from mice with L/+ 
mutation to Apoe-/- recipients resulted in a small decrease in plaque size compared to the recipients 
that received macrophages without the L/+ mutation.  It is likely that balance between increased 
blood pressure with its pro-atherogenic potential and macrophage athero-protective phenotype 




Most individuals with cardiovascular disease (CVD) have multiple risk factors including 
abdominal obesity, dyslipidemia, hypertension, insulin resistance, proinflammtory and 
prothrombotic state, which together constitute the Metabolic Syndrome (MetS) [1].  The increased 
prevalence of obesity and its contribution to the pathogenesis of cardiovascular disease is of major 
concern.  Although insulin resistance is a significant component of MetS, diabetes by itself can 
make patients more susceptible to atherosclerotic disease and also increases the severity of pre-
existing cardiovascular disease.  Many diabetic patients are being treated with Peroxisome 
Proliferator Activated Receptor (PPARγ) agonist Thiazolidinedione drugs which act as insulin 
sensitizers.  Using mouse models of atherosclerosis lacking apolipoprotein E (apoE) or low density 
lipoprotein receptor (LDLR), several studies have established the anti-atherosclerotic effects of 
PPARγ agonists [2, 3, 4].  PPARγ is a nuclear receptor, and amongst its myriad functions, is 
necessary for adipocyte differentiation and triglyceride deposition [5].  PPARγ is expressed in 
activated monocytes and tissue macrophages and has been demonstrated in the foam cells of an 
atherosclerotic plaque [6, 7].  PPARγ has emerged as an important regulator of scavenger receptor 
CD-36 that can affect lipid accumulation in the macrophages [8].  On the other hand, a PPARγ-
LXR-ABCA-1 axis has been implicated in lipid efflux from the macrophages [9].  Consistent with 
this knowledge, high fat fed LDLR-deficient mice reconstituted with bone marrow from a 
conditional knockout of macrophage PPARγ had increased atherosclerosis compared to control 




In addition to the macrophage, PPARγ is expressed in endothelial [11] and vascular smooth muscle 
cells [12] and plays a role in blood pressure regulation.  A two fold genetic increase or decrease in 
PPARγ expression decreases or increases blood pressure by ~3 mmHg respectively [13].  
Endothelial PPARγ appears to be essential for the hypotensive effects of Rosiglitazone [14] and 
Rosiglitazone has been shown to improve the impaired acetylcholine-induced relaxation of carotid 
arteries in hypertensive mice over-expressing both human rennin and angiotensin transgene [15].  
However, PPARγ deficient mice rescued from embryonic lethality have hypotension, suggesting a 
complex role for PPARγ in blood pressure regulation [16].   
 
Various point mutations in PPARγ that affect adipose tissue distribution and insulin sensitivity 
have been identified in humans.  Among these, the dominant-negative heterozygous PPARG-
P467L mutation, which results in decreased PPARγ activity, was originally identified in patients 
with severe insulin resistance, hyperglycemia, lipodystrophy and hypertension [17].  Mice 
heterozygous for the corresponding PpargP465L/+ mutation (L/+ or L) also have ~7mmHg higher 
blood pressure than normal and have mild hyperinsulinemia and increased pancreatic islet mass, 
especially on high-fat diet [18].  They exhibit normal plasma glucose and insulin sensitivity [18, 
19], unless they are stressed by severe obesity [19] or by suppression of insulin production 
(Pendse, Chapter 3).  In this study, we hypothesized that the L/+ mutation that dominant negatively 
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reduces PPARγ activity and causes hypertension, hyperinsulinemia will worsen atherosclerosis in 
Apoe-/- mice.  Although the L/+ mutation itself is a rare occurrence, several point mutations that 
have been identified in the ligand binding domain of PPARγ share somewhat similar phenotype 
that prominently includes reduced sensitivity to insulin.  Here, we attempt to understand the impact 
of altered PPARγ function on atherosclerosis, in a context possible in the human population.  We 
found that PPARγP465L/+;Apoe-/- (Lee) macrophages, in culture, had a significant reduction by about 
11% in their DiI labeled VLDL uptake from the media compared to macrophages isolated from the 
Apoe
-/- (Wee) controls.  However, overall atherosclerosis lesion size in the two genotypes is not 
different, suggesting that a reduction/ alteration in PPARγ function (due to P465L mutation) does 
not have a significant effect on plaque size in Apoe deficient mice.  
4.3 Methods 
Generation of Mutant Mice and Diet: Mice deficient in Apoe and harboring a PpargP465L/+ 
mutation (Lee) were generated by crossing Apoe-/- mice with heterozygous PpargP465L/+ mice.  
Both the mutations are on the identical 129/SvEvTac background. Littermate Apoe-/- mice with 
(Lee) or without (Wee) were used for experiments.  The mice were fed normal rodent chow (Lab 
Diet 5P76; PMI Nutrition International, Richmond, Indiana, USA), or a high fat western type diet 
containing 21% (w/w) fat and 0.15% (w/w) cholesterol (TD88137; Harlan Teklad, Madison, WI, 
USA).  The mice were maintained in a temperature controlled environment at a 12 hour light and 
dark cycle. They had free access to food and water except when fasting blood samples were 
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obtained. The animals were handled following procedures approved by the Institutional Animal 
Care and Use Committee at The University of North Carolina at Chapel Hill.  
 
Mouse Genotype Analysis: DNA samples were obtained from mouse tails and amplified in PCR 
reactions using Applied Biosystmes 2720 Thermal Cycler. Primers used for ApoE genotyping are 
5’-primer (Intron 3) AGA ACT GAC GTG AGT GTC CA, 3’-primer (Intron 3) GTT CCC AGA 
AGT TGA GAA GC and Neo (3’ end) CTT CCT CGT GCT TTA CGG TA. Primers used for 
PPARγ genotyping were 5’-primer CAC GAA TCA CCA GCA ACA TG and 3’-primer CCC 
ATT CTT GTC ATG ATT CCC.  
 
Measurement of Plasma Glucose and Lipids: Animals were fasted for 4 hours and plasma 
glucose and cholesterol were measured in colorimetric assays from Wako Chemicals USA Inc 
(Richmond, Virginia). Plasma Triglyceride levels were determined using an enzymatic assay from 




Blood pressure (BP) measurements:  BP and pulse rate were measured by the tail-cuff method 
and were calculated from the mean of the 30 daily measurements each day for 6 consecutive days 
[20].  
 
Determination of Atherosclerotic Lesion Size: Mice were sacrificed using an overdose of 
Avertin and perfused with Heparinized PBS followed by 4% paraformaldehyde. The heart with the 
aorta was then cut out, embedded in paraffin blocks, aortic root serially sectioned and stained with 
Sudan IV and Hematoxylin.  Four sections, from anatomically defined positions in the aorta, were 
used for quantitative assessments of the atherosclerotic plaques and their mean was used as a 
measure of lesion area [21].  
 
Triglyceride secretion assay:  In order to estimate liver TG secretion, a 10% solution of Triton 
WR-1339 (Tyloxapol, Sigma-Aldrich) in 0.9% saline was injected into the tail vein at a dose of 0.7 
mg/g body weight (total injected volume was ~ 200µl).  Blood was collected at time 0 and at 
specified times after tyloxapol injection and plasma TG concentrations (mg/dl) were then 
measured and normalized to body weight [22].  The TG values were plotted against time for each 
genotype and a linear curve fit was performed.  The slopes from the curve fit equations were used 




Fat tolerance test:  At 5 months of age, male mice of each genotype fed normal chow were fasted 
for 4h and the animals were challenged with 250uL of olive oil.  Plasma was collected for 
triglyceride measurement at 0, 1, 2, 4 and 6 hour after oral gavage [23].  
 
Isolation of peritoneal macrophages and VLDL uptake:  Mice were given intraperitoneal 
injections of sterile 4% thioglycollate (BD Biosciences) in PBS.  Four days later, macrophages 
were collected by peritoneal lavage into PBS after sacrifice by cervical dislocation [24].  
Macrophages were either directly used for gene expression analyses or washed with Ham's nutrient 
mixture F-10 medium (F-10), spun at 1000 × g for 5 min, and plated in 12-well plates at a density 
of 6 × 105 cells/well in F-10 medium supplemented with 10% fetal bovine serum, 100 units/ml 
penicillin, 100 µg/ml streptomycin, and 2 mM L-glutamine. Cells were washed 2 h later to remove 
non-adherent cells and cultured in medium without fetal bovine serum for 24 h before measuring 
VLDL uptake.  Mouse VLDL fractions were isolated from pooled plasma of Apoe-/- mice, by 
ultracentrifugation at d < 1.006 and were labeled with 1,1′-dioctadecyl-3,3,3′,3′-
tetramethylindocarbocyanine perchlorate (DiI C18; Molecular Probes, Inc., Eugene, OR) [25].  
Macrophages in culture were incubated with medium containing 1 µg/ml of DiI-labeled mouse 
VLDL. After 2 h, cells were washed with fresh medium, lysed and fluorescence was observed with 
an IX70 inverted microscope (Olympus) equipped with a filter set for Texas red (exciter 560/55, 
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dichroic 595, emitter 645/75; Chroma Technology Corp.) [24]. Fluorescence pixel intensity of each 
cell was recorded with a SPOT RT Slider digital camera and analyzed with SPOT version 4.0.9 
(Diagnostic Instruments) and ImageJ 1.33u software (National Institutes of Health). 
 
Bone Marrow Transfer:  Bone marrow cells were collected from the femurs and tibias of donor 
Lee and Wee male mice by flushing with F-10 medium. Recipient female Apoe-/- mice (Wee), 6–8 
weeks of age, were lethally irradiated (9.5 grays) and injected with 2 × 106 bone marrow cells in 
0.2 ml of medium through tail veins. For 2 weeks after transplantation, mice were given drinking 
water acidified to pH 2.0 by HCl and containing 100 mg/liter neomycin [24]. 
 
Gene expression:  Total RNA was purified using Automated Nucleic Acid Workstation ABI 
6700, and real-time PCR was performed in ABI PRISM 7700 Sequence Detector (Applied 
Biosystems).  β-Actin mRNA was used for normalization.   
 
ABCA1 Forward CAG ATC TAT AGG AGG AAG CG 
Reverse GTT AAC TCC CAG GAG TCC AA 
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Probe f TGC ATC GGC ATC CCT CCC G q 
CD36 Forward GCC AAG CTA TTG CGA CAT GA 
Reverse AGA ATC TCA ATG TCC GAG ACT 
Probe f CAC AGA CGC AGC CTC CTT TCC ACC q 
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CCR2 Forward GAT GAT GGT GAG CCT TGT CA 
Reverse ACC AAA GAT GAA TAC CAG GGA 
Probe f ATT GGA GCT TGG ATC CTG CCT CCA CT q 
NF-kB Forward AAG TGA TCC AGG CAG CCT TC 
Reverse CTA TGT GCT GCC TCG TGG AG 
Probe f TCA GGT CCA CTG TCT GCC TCT CTC GTC q 
Data analysis:  Values are reported as mean±SEM.  Student’s t test was used for comparisons 
between genotypes, and differences were considered to be statistically significant if p< 0.05. 
4.4 Results 
Phenotype of Lee and Wee mice:  Lee and Wee mice were born in the expected mendelian ratio.  
They appeared healthy and gained weight normally.  General 
phenotypes of normal chow and high fat diet fed Wee and Lee mice are shown in table 4.1.   
Blood pressure in 4 month old male Lee mice was significantly elevated compared to Wee 












Table 4.1: Phenotypes of normal chow and high fat diet fed male Wee and Lee mice.  GF, 
Gonadal Fat; HFD, high fat diet; IF, Inguinal Fat; NC, normal chow. 
 NC (Age = 5 mo) HFD (Age = 4 mo with 2 mo 
on HFD) 
 Wee Lee P Wee Lee P 
BP (mmHg) 
Male 
































































The difference in blood pressure between the two genotypes was retained with high fat diet feeding 
for 2 months (from 2 months of age to 4 months of age).  We noticed no gender differences 
between parameters measured in the two geneotypes.  The plasma glucose levels were similar in 
the two groups; the plasma TG levels were lower in the normal chow fed Lee animals, although the 
difference was not statistically significant.  Plasma TG levels increased in both genotypes in 
response to high fat feeding and Lee mice had significantly lower TG levels in plasma compared to 
Wee controls.  Plasma cholesterol was not different between the two genotypes on normal chow 
diet.  Cholesterol levels increased in both genotypes upon high fat diet feeding; however, there was 
no genotype difference.    
Although the mice of the two genotypes had similar body weights and similar total body fat 
content, there was a difference in their fat distribution pattern.  Lee mice had a smaller visceral 
gonadal adipose tissue but a larger subcutaneous inguinal adipose tissue when compared to the 
corresponding fat depots in the Wee mice (gonadal fat/body weight: Wee, 1.76±0.16; Lee, 
1.08±0.14 and inguinal fat: Wee, 1.18±0.14; Lee, 1.49±0.13; p<0.05).  Thus, Lee mice had a 
significantly higher inguinal to gonadal ratio (IF/GF ratio) when compared to the Wee littermate 
controls.  High fat feeding increased the total amount of adipose tissue in both genotypes (gonadal 
fat/body weight: Wee, 3.67±0.25; Lee, 3.05±0.28 and inguinal fat: Wee, 2.52±0.35; Lee, 
3.09±0.39; p<0.05).  However, the fat distribution, represented by I/G ratio was maintained similar 
to that on a regular chow diet.  We next measured the average size of the atherosclerotic plaques in 
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serial sections of the aortic root in 5 month old regular chow fed mice and 6 month old mice fed 























Figure 4.1: Atherosclerotic plaque size in normal chow and high fat diet fed Wee and Lee 
mice.  NC, normal chow; HFD, high fat diet.  Sample size for Wee, NC = 29; Lee, NC = 24, 
Lee, NC = 25 and Lee, HFD = 19.  Data obtained from both male and female mice.  White 
bars represent Wee mice, black bars represent Lee mice. 
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The lesion size in Wee and Lee mice did not differ from each other in either dietary condition 
(Wee NC, 0.68±0.09; Lee NC, 0.59±0.1; Wee HF, 0.89±0.11; Lee HF 0.81±0.12 x 105 µm2; table 
4.1).  We did not notice any difference in the plaque composition based on histological assessment.       
 
Due to the trend towards lower plasma TG in Lee mice, we investigated the liver in regular chow 
fed Lee and Wee mice.  In 5 month old males, the liver weight was significantly smaller in Lee 
mice than that in Wee controls (Wee, 1.243±0.045, n= 5; Lee, 1.038±0.073 mg, n=5; p<0.05; Fig 
4.2A).  Despite the lower liver weight, the Lee livers had a higher TG (Wee, 2.76±0.31, n=5; Lee, 
3.57±0.53, n=3 mg/g protein; p=NS; Fig 4.2C) and cholesterol per gram of protein (Wee, 
1.04±0.027, n=5; Lee, 1.51±0.039 mg/g of protein, n=3; p<0.05; Fig 4.2C), although only the 










Figure 4.2:  Liver phenotypes in Lee and Wee mice.  Liver weight normalized to body weight 
(A), TG levels during lipid tolerance test (B), Liver triglyceride and cholesterol content 
normalized to protein (C) and liver triglyceride secretion after tyloxapol injection to prevent 
lipoprotein uptake (D) in 5 month old normal chow fed male mice.  Dashed lines and white 
bars represent Wee mice, solid lines and black bars represent Lee mice.  









































































To examine the post-prandial lipid handling, which can affect the outcome of an atherosclerotic 
lesion, we performed a lipid tolerance test in 5 month old male mice.  TG levels in plasma samples 
collected after a 4 hour fast following an olive oil gavage were similar in the Lee and Wee mice 
(Fig 4.2B).  These TG values are a function of lipid absorption, rate of clearance and liver TG 
synthesis and secretion.  Since the TG and cholesterol content is higher in the Lee livers, we 
specifically looked at the secretion of TG from the livers.  In an in vivo experiment where the 
lipoprotein particles coming from the livers of fasted mice were coated with Tyloxapol to prevent 
their uptake and clearance from plasma, we detected no difference in liver TG secretion between 
Lee and Wee mice (Fig 4.2D).      
Despite a consistent, small yet significant increase in the blood pressure of Lee mice, the presence 
of PPARγP465L/+ mutation does not affect the atherosclerotic plaque size in apoe-/- mice.  It is 
likely that the pro-atherogenic effect of the higher blood pressure may be counteracted by a 
presence of lower plasma TG levels and a favorable adipose tissue distribution pattern 
characterized by an increase in subcutaneous fat.  
 
Macrophage function and bone marrow transfer:  PPARγ is expressed at high levels in the 
macrophages and macrophage derived foam cells in atherosclerotic plaques [6, 7].  To investigate 
whether P465L/+ mutation in the ligand binding domain of PPARγ affects macrophage function in 
apoe-/- mice, we isolated thioglycollate-stimulated peritoneal macrophages from Lee and Wee 
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mice.  Gene expression studies revealed a significant increase in ABCA-1 and a small decrease in 







Figure 4.3: Macrophage gene expression and lipid uptake. (A) Gene expression data 
normalized to β-actin from primary macrophages isolated after thioglycollate injection. (B) 
DiI labeled VLDL uptake from the media by macrophages. ABCA-1, ATP binding cassette 
transporter protein; CD36, scavenger receptor-36; CCR2, CC chemokine receptor-2; NF-κB, 
nuclear factor- κB. Sample size for macrophages from Wee = 9 wells from 3 mice, Lee = 10 
wells from 3 mice.  White bars represent Wee mice, black bars represent Lee mice. 

























































Since ABCA-1 stimulates cholesterol efflux, and CD-36 facilitates the uptake of oxidized LDL, 
this gene expression data suggests reduced lipid accumulation in Lee macrophages.  Other genes 
including CCR2 and NF-κB were not significantly different between the two genotypes, 
suggesting that the inflammatory response is not altered in Lee macrophages.  In agreement with 
the gene expression data, we found that Lee macrophages, had a significant reduction by about 
11% in their DiI labeled VLDL uptake from the media in culture, compared to macrophages 
isolated from the Wee controls (Fig 4.3B).  Thus, the presence of L/+ mutation reduced 
macrophage lipid accumulation via modulation of ABCA-1 and CD36 gene expression.   
 
We next tested whether the reduced lipid content in the Lee macrophages would reduce the 
atherosclerotic lesion size in ApoE-/- mice.  A bone marrow transfer experiment was performed by 
harvesting the bone marrow from Lee and Wee male mice and transplanting it into the Wee female 
recipients.  Two months after the transfer, the plaque size in mice that received Wee bone marrow 








Figure 4.4: Atherosclerotic plaque size in chow fed female mice reconstituted with Wee and 
Lee bone marrow.  P value = 0.19.  Sample size for Wee = 9 and Lee = 10.  White bars 
represent Wee mice reconstituted with Wee bone marrow, black bars represent Wee mice 


























 mice with PPARγP465L/+ mutation have a significantly higher blood pressure, by ~7 
mmHg, compared to Apoe-/- controls.  Using mice deficient in endothelial nitric oxide synthase, 
higher blood pressure has been shown to increase atherosclerotic lesions in the aorta of apoE-/- 
mice [26, 27].  Thus, we hypothesized that the higher blood pressure due to PPARγP465L/+ 
mutation will have a pro-atherogenic effect in apoE-/- mice.  Despite higher blood pressure, the 
plaque sizes in regular chow and high fat fed Lee mice did not differ from the Wee littermate 
controls.  Induction of hyperglycemia with streptozotocin and thiazolidinedione treatment of the 
Wee and Lee mice did not reveal any genotype differences (data not shown).  The blood pressure 
in eNOS-/-;apoE-/- or NPRA-/-,apoE-/- double knowckout mice is much higher, ~20mmHg, 
compared to the increase of ~ 6 mmHg caused by the PPARγP465L/+ mutation [26, 28].  It is 
likely that in the presence of strongly atherogenic apoE deficient state, a small increase in blood 
pressure in not sufficient to worsen atherosclerosis.  While drugs inhibiting both rennin-
angiotensin system and diuretics effectively lowered atherosclerosis, treatment of eNOS-/-;apoE-/- 
mice with Hydralazine at a dose that lowers blood pressure levels to those seen in apoE-/- mice did 
not improve the outcome of atherosclerosis [26, 29].  Hypertension by itself may not influence 
atherosclerosis development significantly without a contribution of macrophage dysfunction and 




In our experiments using the Lee double mutant mice, generated from a cross between L/+ and 
Apoe
-/- mice, it is not possible to differentiate between the contribution of the mutant PPARγ in 
macrophage and foam cells versus its global direct and indirect effects on plasma lipid levels, 
blood pressure and adipose tissue function.  It is likely that the roles of PPARγ in macrophage 
versus the vessel wall have opposing effects, resulting in an unchanged atherosclerotic lesion in 
Lee mice.  Thus, we specifically examined the role of PPARγP465L/+ mutation in peritoneal 
macrophages.  PPARγ is expressed at high levels in the macrophages and macrophage derived 
foam cells in atherosclerotic plaques [6, 7].  It plays a complex and multi-faceted role in 
macrophages affecting the activation and recruitment of foam cells to the plaques, cholesterol 
homeostasis and inflammation.  PPARγ agonists have been shown to inhibit atherosclerosis in 
LDL receptor deficient and apoE knockout mice [2, 3, 4].  Babaev at al showed that a knockout of 
macrophage PPARγ increased atherosclerosis in C57BL/6 and LDL receptor deficient mice [10].  
The conditional disruption of PPARγ in murine macrophages regulates cholesterol efflux via 
reduction in ABCA-1 transcription.  ABCA-1, a member of the ATP-binding cassette (ABC)-
transporter family, is crucial for the high density lipoprotein (HDL) and apolipoprotein A1 (apoA1) 
mediated cholesterol efflux from macrophages [30].  PPARγ has been shown to induce 
macrophage ABCA-1 expression, via the mediation of LXR [9].  Additionally, TZDs up-regulate 
ABCA-1 expression, a phenomenon which is not seen in macrophages deficient in PPARγ.  Thus, 
ABCA-1 mediated cholesterol efflux from the macrophage may contribute to the anti-atherogenic 
effect of PPARγ as well as its ligands.  In contrast with the above findings, we found that the apoe-
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/- macrophage with the dominant negative P465L/+ mutation had a higher expression of ABCA-1 
compared to apoe-/- macrophage with wild type PPARγ.  It is possible that this unexpected effect 
of L/+ mutation on ABCA-1 expression is attributable to altered function of the mutant PPARγ 
allele, rather than due to dominant negative reduction in the wild type allele in presence of L/+ 
mutation.    
 
PPARγ is also shown to be an important regulator of the scavenger receptor CD36, which is 
associated with lipid accumulation in the macrophage [6, 8].  Although treatment of wild type but 
not PPARγ deficient macrophages with rosiglitazone resulted in a robust upregulation of CD36 
expression, the basal gene expression level for CD36 were fairly similar between wild type and 
PPARγ deficient macrophages.  However, in our Lee mice with the PPARγP465L/+ mutation, the 
gene expression of CD36 in thioglycollate-induced macrophages is lower by ~25% than Wee 
macrophage, with the difference approaching statistical significance.  It is likely that these 
differences in basal gene expression contribute to the reduced lipid accumulation in Lee 
macrophages, which was confirmed by a small yet significant reduction in their DiI labeled VLDL 
uptake from the media compared to macrophages isolated from the Wee controls.  In spite of this 
athero-protective phenotype in the Lee macrophages, the bone marrow transfer experiment, set up 
to study the effect of macrophage PPARγ mutation, did not reveal a protective effect on plaque 




Thus, the reduced PPARγ activity and/or an altered function of the mutant protein in mice 
harboring the PPARγP465L/+ mutation affects the expression of target genes differentially 
compared to its complete absence.  Thus variation in the amount or activity of PPARγ protein, 
which may naturally exists in the human population or due to the effect of TZD treatment, can 
modulate the lipid accumulation in the macrophage potentially influencing atherosclerosis.   
 
The pro-atherogenic effect of the higher blood pressure in Lee mice is likely to be counteracted by 
the anti-atherogenic effect caused by a protective phenotype in the Lee macrophages.  However, 
when the hypertensive effect of the PPARγP465L/+ mutation was eliminated in the bone marrow 
transfer experiments, plaques in mice transfected with L/+ bone marrow were only somewhat 
smaller than the wild type controls.  The protective phenotype suggested by the in vitro 
experiments in Lee macrophages did not bring about an overt reduction in the atherosclerosis 
lesions in the bone marrow transfer experiments.    
 
In addition to adipose tissue, where PPARγ is essential for the development and optimum function, 
deficiency of macrophage PPARγ reduces apoE gene expression and its protein level in the plasma 
[31].  ApoE has been recognized to regulate cholesterol efflux from macrophages [32].  Thus, 
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apoE null macrophages have reduced cholesterol efflux to HDL3 and apolipoprotein A1 explaining 
the observation by Fazio et al that transplantation of bone marrow derived from apoE deficient 
mice into C57BL/6 mice leads to a significant increase in atherosclerotic lesion size [33, 34].  The 
possibility that PPARγ mutation may differentially alter the phenotype of some other model of 
atherosclerosis, such as LDLR-/- mice which retain endogenous apoE, can not be denied. 
 
It is important to acknowledge that PPARγ is identified as a crucial athero-protective molecule in 
the experimental setting of its complete lack in a specific tissue while present in the rest of the 
body.  Unlike the tissue specific knock-out mice, a reduction in functional PPARγ due to P465L 
mutation in the whole body resembles a phenotype due to human mutations and polymorphisms 
more closely.  This model takes into consideration, the potential cross talk between different cell 
and organ systems, which seems to dampen the potential deleterious effects in a single cell type/ 
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APOLIPOPROTEIN E KNOCK-OUT AND KNOCK-IN MICE: ATHEROSCLEROSIS, 
METABOLIC SYNDROME AND BEYOND. 
(This chapter consists of material from a manuscript reprinted with permission from JLR; 2009 
Apr;50 Suppl:S178-82. Epub 2008 Dec 5; titled “Apolipoprotein E knock-out and knock-in mice: 
atherosclerosis, metabolic syndrome and beyond” by Pendse AA, Arbones-Mainar JM, Johnson 




Given the multiple differences between mice and men, it was once thought that mice could not be 
used to model atherosclerosis, principally a human disease.  Apolipoprotein E deficient (apoEKO) 
mice have convincingly changed this view, and the ability to model human-like plaques in these 
mice has provided scientists a platform to study multiple facets of atherogenesis and to explore 
potential therapeutic interventions.  In addition to its well-established role in lipoprotein 
metabolism, recent observations of reduced adiposity and improved glucose homeostasis in 
apoEKO mice suggest that apoE may also play a key role in energy metabolism in peripheral 
organs including adipose tissue.  Finally, along with apoEKO mice, knock-in mice expressing 
human apoE-isoforms in place of endogenous mouse apoE have provided insights into how 
quantitative and qualitative genetic alterations interact with the environment in the pathogenesis of 
complex human diseases. 
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Apolipoprotein E (apoE) plays a central role in lipoprotein metabolism and is required for the 
efficient clearance of diet-derived chylomicrons and liver-derived very low density lipoprotein 
(VLDL) remnants by the liver (1).  Consequently, mice lacking apoE (apoEKO) provided the first 
practical model of hyperlipidemia and atherosclerosis.  In this review, we revisit the primary 
features of lipoprotein metabolism and atherosclerosis in apoEKO mice and the contributions of 
human apoE isoforms using the apoE knock-in mice.  We then extend our discussion to more 
recent observations that suggest an important role for apoE in peripheral energy metabolism and 
consequently in metabolic syndrome and its components, mainly obesity and diabetes.    
 
Lipoprotein metabolism in apoEKO mice:  Plasma cholesterol in wild type mice on a regular 
chow diet is approximately 80 mg/dl, primarily carried in high density lipoprotein (HDL) particles.  
Mice have a small amount of low density lipoprotein (LDL) and other atherogenic lipoproteins, 
such as VLDL remnants.  This high HDL to LDL ratio is maintained even when mice are fed diets 
similar to those consumed by humans in Western society.  This is in marked contrast to humans 
who carry the majority of their plasma cholesterol in the LDL (110 mg/dl) (2).  It is well 
established in humans that a low ratio of HDL to LDL cholesterol confers a high risk of 
atherosclerosis and subsequent cardiovascular disease (3). Thus, the natural athero-protective 
lipoprotein profile in mice could account for the absence of these pathologic conditions.   
 
133 
In spite of the different plasma lipid profiles, cholesterol transport and metabolism are sufficiently 
similar in the two species to suggest that inducing suitable disturbances in plasma lipoprotein 
metabolism would also lead to atherosclerosis in mice.  Gene targeting in embryonic stem cells 
developed during the 1980s (4-6) opened the door to test this concept, and mice homozygous for a 
defective apolipoprotein E gene were produced by us and independently by Plump et al. in 1992 
(7-9).   
Although extremely rare, humans lacking apoE are reported to have elevated remnant cholesterol 
in plasma (10).  Similar to these individuals, apoEKO mice accumulate cholesterol-rich remnant 
particles with plasma cholesterol levels reaching 400 mg/dl, even when fed a regular low-fat, low-
cholesterol diet.   
 
Atherosclerosis in apoEKO mice:  Although atherosclerosis is not a distinguishing feature 
described in apoE-deficient humans (10), apoE-deficiency alone proved to be sufficient for aortic 
atherosclerotic plaques to develop in mice.  In addition, diets high in fat and cholesterol markedly 
accelerate plaque development in these mice.  Thus, apoEKO mice, and subsequently mice lacking 
the LDL receptor (LDLR) that develop severe atherosclerosis on a Western-type diet (11), have 




The lesion development and plaque composition in apoEKO mice is also similar to that in humans, 
establishing it as an excellent animal model for studying the pathogenesis of atherosclerosis.  A 
small collection of foam cells that are tightly adhered to the aortic valve begin to appear in mice at 
about two months of age.  With time the complexity of the lesion increases to have fibrous caps, a 
necrotic core of foam cell debris, cholesterol crystals and calcifications.  Large advanced plaques 
are often associated with the thickening of medial and adventitial tissue, accompanied by chronic 
inflammation. Lesions with spontaneous hemorrhage and rupture, the features associated with 
clinical symptoms of human atherosclerosis, have been observed in some studies of older, 
cholesterol-fed mice (12, 13).  However, the occurrence of these events in 
apoEKO mice is not sufficiently reliable, leaving room for improvement in studying the plaque 
rupture process.   
ApoEKO mice have been extensively used for several years to study the impact of various genetic 
and environmental risk factors on atherosclerotic susceptibility and resistance and to evaluate the 
effects of various therapeutic means.  These studies have been comprehensively reviewed 
elsewhere (14).  
 
Mice with human apoE isoforms:  While the apoEKO mouse has been established as an 
excellent model of atherosclerosis, the lack of apoE is extremely rare in the human population.  
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However, apoE is polymorphic in humans, and plasma LDL cholesterol levels and atherosclerosis 
risk are both strongly associated with the three common apoE isoforms in the order of apoE4 > 
apoE3 > apoE2.  This association is rather counterintuitive because apoE4 (Arg-112, Arg-158) 
binds to LDLR with a slightly higher affinity than apoE3 (Cys-112, Arg-158), while apoE2 (Cys-
112, Cys-158) binds to the receptor with much reduced affinity (15). 
Unlike in humans, the plasma lipoprotein profiles in apoE knock-in mice expressing the human 
apoE proteins in place of mouse apoE are reflective of their different LDLR affinities. Thus, mice 
with apoE3 and apoE4 are normolipidemic and do not develop atherosclerosis even on a Western-
type diet (15).  In contrast, mice with human apoE2, which binds to LDLR with less affinity, 
accumulate plasma remnants with high cholesterol and triglycerides (TG), and develop 
atherosclerosis (16). 
Surprisingly, however, mice with human apoE2, E3 or E4 recapitulate the lipoprotein profiles of 
their human counterparts when they also express a high amount of the human LDLR and are fed a 
Western-type diet (17).  Thus, an increased expression of LDLR in mice with human apoE4 causes 
an accumulation of cholesterol-rich, apoE-poor remnants in plasma, a reduction of HDL, and 
severe atherosclerosis.  In marked contrast, the same increase in LDLR in apoE2 mice ameliorates 
their hyperlipidemia and diet-induced atherosclerosis.  These results raise the possibility that 
apoE4, by binding strongly to excess LDLR, is prevented from transferring to nascent lipoproteins, 
a step necessary for their subsequent clearance.  This in turn leads to an increase in the plasma 
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concentration of apoE-poor remnants.  Indeed, we found that primary hepatocytes from apoE4 
mice secrete less apoE into the medium than hepatocytes from apoE2 mice.  Increased LDLR 
expression leads to a localization of apoE4 on the hepatocyte surface and enhances sequestration of 
apoE-deficient VLDL remnants injected into apoE4 mice.  However, these surface-bound VLDL 
were poorly internalized compared to apoE2 mice (18). 
ApoE isoform-dependent changes in cholesterol uptake and efflux from macrophages have been 
reported (19, 20).  Cholesterol delivery to macrophages in culture increases as LDLR expression 
increases, and the effect was more prominent in apoE4 macrophages than those with apoE3 (21).  
Conversely, increased LDLR expression reduces cholesterol efflux from macrophages expressing 
apoE4 but not apoE3 (22).  Consequently, in mice with human apoE4 that lack the LDLR 
(LDLRKO), the replacement of bone marrow cells with cells expressing LDLR increased 
atherosclerosis in a dose dependent manner compared to mice transplanted with LDLRKO cells.  
In contrast, atherosclerosis in LDLRKO mice expressing human apoE3 was not affected by the 
bone marrows with varying levels of LDLR expression (22).  Although further tests are required to 
extrapolate these findings in mice to humans, interactions between apoE-isoforms and LDLR in 





ApoEKO mice and adipose tissue biology:  In addition to its primary site of synthesis in the 
liver, apoE is also synthesized in peripheral tissues including adipose tissue (23, 24).  Recent 
studies indicate that apoE may be a crucial player in peripheral lipid uptake and energy 
homeostasis and consequently in the development of metabolic syndrome (MetS).  MetS is a 
combination of several conditions including obesity, hyperglycemia, hyperinsulinemia, 
dyslipidemia, hypertension, and a prothrombotic, proinflammatory state (25). Obesity is a 
prominent aspect of MetS, and adipose tissue is now considered to be an important regulator of 
energy metabolism. Expression of apoE in adipocytes decreases in response to obesity and TNF-α, 
but increases with fasting and weight loss (26, 27).  ApoE expression is regulated by nuclear 
receptors such as liver X receptor and Peroxisome Proliferator Activator Receptor 
γ (PPARγ), which is vital for adipocyte differentiation (28).  
ApoEKO mice are leaner than wild-type mice (29-31).  Absence of apoE also reduces body weight 
and some of their obesity-associated metabolic complications including impaired glucose tolerance 
and insulin resistance in obese models such as ob/ob and Ay/+ mice (30, 32, 33).  Impaired 
delivery of liver-derived VLDL to adipocytes could partly account for the suppressed body weight 
gain and fat accumulation in apoEKO mice.  In the adipocyte, apoE interacts with the VLDL 
receptor (VLDLR), which facilitates hydrolysis of TG by lipoprotein lipase (LPL) (34). Indeed, 
mice lacking the VLDLR are protected from obesity (35).  Chiba et al. (30) showed that wild type 
VLDL, but not VLDL from apoEKO mice, induces differentiation of bone marrow stromal cells 
and 3T3-L1 cells into adipocytes. However, LPL inhibition did not alter the adipogenic activity of 
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VLDL, suggesting that apoE-mediated VLDL uptake, but not hydrolysis of VLDL, plays a major 
role in adipogenesis.    
Modulation of adiposity and tissue insulin sensitivity by adipose-derived apoE is suggested by the 
work of Huang et al., who showed that apoE synthesized by adipocytes promotes TG uptake in 
culture, and that the lack of endogenous apoE led to a marked defect in TG uptake from exogenous 
VLDL even when the VLDL contained apoE.   The uptake was restored by adenoviral expression 
of apoE (36). The authors further showed that a PPARγ agonist increased apoE expression and TG 
accumulation in wild type adipocytes, but the same PPARγ stimulation produced significantly less 
TG synthesis and TG accumulation in apoEKO adipocytes.  Thus, adipose-derived apoE may play 
a role in intracellular lipid storage in an autocrine and/or paracrine fashion.  Further studies are 
necessary to determine the relative roles of lipoprotein-associated, circulating apoE and apoE 
synthesized by adipose tissue in metabolic homeostasis.  
 
Human apoE isoforms and adiposity:  Epidemiological studies have suggested that the apoE 
polymorphism modifies a long recognized association between increased body fat, particularly 
abdominal fat, and increased plasma VLDL in humans (37).  For example, in the Heritage Family 
Study population, a pleiotropic Quantitative Trait Locus for TG and adiposity was found on 
ch19q13 where APOE is located (38).  ApoE-isoforms were associated with body mass index in 
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the order of apoE4<apoE3<apoE2 in 15,000 individuals from the Atherosclerosis Risk in 
Communities (ARIC) study (39).  
Similar to their human counterparts, mice expressing human apoE3 gain more body weight and 
adipose tissue mass than mice with apoE4 when fed a Western type diet.  Despite being leaner, 
apoE4 mice begin to show impairment of glucose tolerance earlier than apoE3 mice, mainly 
because adipocytes expressing apoE4 fail to buffer postprandial lipids and glucose completely 
(40).  Adenoviral expression of apoE3 in cultured apoE-null adipocytes induced mRNA expression 
for adiponectin in a dose dependent manner, but the induction was significantly blunted in cells 
expressing apoE4.  ApoE4 expression increased mRNA for Glut1, but not Glut4, in adipocytes, 
suggesting that apoE4 may be interfering with insulin-regulated pathways.  These apoE isoform-
dependent effects on body fat are a reminder that in addition to total fat mass, the functionality of 
fat cells is also an important determinant of disease risk.  
 
ApoE in diabetes and beyond:  Cardiovascular incidents as a consequence of atherosclerosis are 
significantly increased in diabetic patients.  Multiple diabetic atherosclerosis studies have 
employed apoEKO mice to induce diabetes with streptozotocin (STZ) injection, which ablates the 
insulin producing beta-cells in the pancreas.  The resulting type 1 diabetes accelerated 
atherosclerosis development in apoEKO mice in association with an increase in plasma cholesterol 
levels (41).  However, the diabetes-induced enhancement of atherosclerosis is attenuated, without a 
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significant change in plasma lipid levels, by the administration of the soluble receptor for advanced 
glycation end products (42), rosiglitazone (43), or lipoic acid (44), among others.  Thus, the 
increased oxidative stress and inflammation consequent to the high plasma glucose are major 
contributors to accelerated atherosclerosis in diabetes.  
Type 2 diabetes is more common than type 1 diabetes in humans. In contrast to the consistently 
observed increase in atherosclerosis by the STZ-induced type 1 diabetes, data are conflicting 
regarding the effects of type 2 diabetes on atherosclerosis development in apoEKO mice.  For 
example, insulin resistance due to the lack of insulin receptor substrate 2 (Irs2) gene was shown to 
accelerate atherosclerosis development in apoEKO mice (45).  In contrast, a reduction of 
atherosclerosis has been reported in apoEKO mice treated with gold thioglucose to destroy the 
hypothalamic satiety center and to produce type 2 diabetes (46).  Similarly, while leptin receptor 
deficiency (db/db) induces key features of type 2 diabetes in apoEKO mice  including 
hyperglycemia, hyperinsulinemia, dyslipidemia, and accelerated atherosclerosis (47), deficiency in 
the leptin receptor protects LDLRKO mice from atherosclerosis (48).  Conflicting results have 
been reported in apoEKO mice with leptin deficiency (ob/ob); an increased atherosclerosis in 
chow-fed mice by Gruen et al. (49) and smaller plaques in mice fed an atherogenic diet by Chiba et 
al. (50).  While different experimental conditions such as diet and methods employed for 
atherosclerosis evaluation may be contributing to these different outcomes, reconciliation of these 
differences is of great interest because hyperleptinemia and insulin resistance frequently occur 
together in MetS patients.   
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Figure 5.1 illustrates the metabolic roles of apoE in vivo.  ApoE-mediated lipoprotein uptake in 
liver and adipose tissue lowers plasma lipids (left panel).  In contrast, impaired lipoprotein uptake 
by the liver, in the absence of apoE, leads to an increase in VLDL and chylomicron remnants in the 
plasma as well as increased formation of foam cells in the vessel wall and atherosclerosis (right 
panel).  On the other hand, apoE deficiency also reduces adiposity and improves insulin sensitivity, 
which may have an athero-protective potential.  In the studies of diabetic atherosclerosis such as 
those described above, apoEKO mice have provided an effective sensitizer for atherosclerosis, but 
the possibility that apoE may also have direct roles in the pathogenesis of diabetes and its 
complications has not been addressed.  The potential roles of apoE isoforms in MetS and the 
development and progression of diabetic complications highlight the future utility of the apoE-
knock-in mice in elucidating the mechanisms by which apoE exerts isoform-specific effects. 
Our current understanding of apoE in energy metabolism beyond its role in lipoprotein metabolism 
is still far from complete.  The impairments in metabolic disorders have a potential to modulate 
atherosclerosis and cardiovascular disease progression. Similar to their contributions toward the 
understanding of lipoprotein metabolism and pathogenesis of atherosclerosis, apoEKO mice and 




Fig 5.1: Physiological role of ApoE.  ApoE-mediated triglyceride uptake by liver and adipose 
tissue contributes to maintaining normal plasma lipid levels (left panel). Impaired triglyceride 
uptake in liver and adipose tissue in the absence of apoE contributes to the accumulation of 
VLDL and chylomicron remnants in the plasma and foam cell accumulation in the vessel wall 
(right panel). The arrows represent changes in lipid accumulation in different tissues in the 
presence and absence of apoE. ApoE is increasingly becoming important in peripheral energy 
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C h a p t e r  6  
CONCLUSIONS AND SIGNIFICANCE 
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PPARγ is well established as an important gene for adipocyte differentiation and triglyceride 
accumulation; and insulin sensitivity.  The knockout mice lacking PPARγ in specific tissues have 
enabled us to understand some of the basic functions of this gene.  Mutations in PPARγ occur in 
people and are a useful way to learn about PPARγ, beyond its established functions.  Thus, I 
sought to study the human P467L mutation in the ligand binding domain of PPARγ.  Using a 
mouse model carrying the corresponding P465L mutation, I have shown that the heterozygous 
P465L mutation can lead to insulin resistance.    
 
In my experiments, I have shown that the suboptimal levels of insulin (due to Ins2Akita/+ mutation) 
in the presence of P465L mutation affect the development of adipose tissue structure and function.  
In mice lacking PPARγ in adipose tissue, a similar but severe phenotype of lipodystrophy was 
observed.  My data suggests that functional consequences of alterations in PPARγ levels (due to 
various point mutations and/ or polymorphisms) can be modulated by the reduction in the 
availability of insulin.  This interaction between PPARγ and insulin is especially important early in 
the development during adipose tissue differentiation.  
 
In my double mutant LA mice, P465L mutation led to a decrease in insulin levels that were already 
compromised by the akita mutation.  Thus, there is a direct effect in the β-cells where P465L 
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mutation worsened the impact of Akita mutation and this interaction indirectly affected the adipose 
tissue and liver.  PPARγ in liver is essential for the optimum level of TG accumulation in 
hepatocytes.  Liver-specific PPARγ knockout mice have hyperlipidemia and reduced insulin 
sensitivity.  In my model of P465L mice, the liver is not directly affected by the PPARγ mutation.  
In spite of the reduction in functional PPARγ, the lack of an obvious liver phenotype suggests that 
the dependence of liver function on PPARγ availability is much lower compared to that of the 
adipose tissue.  Reduced circulating insulin levels in addition to functional impairment in the 
adipose tissue have indirect effects on the liver, leading to increased gluconeogenesis which 
contributes to the fasting hyperglycemia in LA females.   
 
Ultimately, it is also important to understand that the skeletal muscle in LA mice can maintain a 
fairly normal homeostasis in the face of a scarcity in available plasma insulin as well as reduction 
in functional PPARγ.  The relatively lower levels of PPARγ in skeletal muscle compared to 
adipose tissue may reflect a lesser requirement of PPARγ for the skeletal muscle insulin 




Overall, my project confirms the findings of the tissue specific knockout models of PPARγ.  Most 
importantly, it has allowed me to extrapolate these concepts to the phenotypes in human patients 
and clearly establish that P465L mutation can lead to insulin resistance.   
 
A similar link has not emerged in the second part of my thesis regarding the role of PPARγ in 
atherosclerosis.  Considering the knowledge generated by using PPARγ knockout mice in 
endothelium, macrophages and vascular smooth muscle cells, it can be concluded that intact 
PPARγ function in these organs is important to reduce the severity of atherosclerotic plaques.  
Based on this, we hypothesized that P465L mutation (with reduced functional PPARγ and higher 
blood pressure) will increase the size of atherosclerotic plaques.  Since a global knockout mouse of 
PPARγ does not survive, an attempt to study the effect of the lack of PPARγ on atherosclerotic 
plaques is not possible.  In our model of P465L mice bred to Apoe-/- mice, the plaque size did not 
change.  Our initial experiments with the Lee macrophages suggest a athero-protective phenotype; 
where as the higher blood pressure due to P465L mutation is likely to increase the atherosclerotic 
plaque size.  This leads me to speculatively conclude that the potential pro-atherosclerotic effect/s 
of higher blood pressure and VSMC dysfunction versus anti-atherosclerotic effects suggested by 
macrophage gene expression and reduced VLDL uptake likely act as opposing influences resulting 
in no change in the atherosclerotic plaque size.   
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It is important to acknowledge that PPARγ is identified as a crucial athero-protective molecule in 
the experimental setting of its complete lack in a specific tissue while present in the rest of the 
body.  These models do not accommodate a potential cross talk between different cell and organ 
systems.  Compared to this setting, a reduction in functional PPARγ due to P465L mutation in the 
whole body is a very different scenario and resembles a phenotype due to human mutations and 
polymorphisms more closely.  In the event of a global reduction in PPARγ, the impact on different 
organs seems to dampen the unopposed effect caused by a single cell type/ organ.  In addition to 
the tissue specific knockouts, which are invaluable tools to learn protein functions, my hypothesis 
tested PPARγ function in a clinically relevant, humanized mouse model.  Without undermining the 
role of PPARγ in individual cell types crucial in the development of atherosclerosis, the Lee mouse 
model suggests that the reduction/ alteration in PPARγ function (due to P465L mutation), does not 
have a significant effect on plaque size in Apoe deficient mice.   
 
In the first part of my thesis, the lessons learnt from the tissue specific knockout mice and 
humanized P465L mice were similar and my findings have consolidated the understanding of 
PPARγ function.  In the second part, however, the reconciliation of knowledge acquired from the 
tissue specific knockout mice and the humanized P465L mice is not exactly straight-forward.  
However, it highlights the inter-dependence of organ systems in a systemic, chronic disease state to 
 
153 
ward off the negative impact (in my case the P465L mutation) and maintain a reasonable level of 
physiological function.       
 
Recently, the concept of selective PPAR modulators, similar to the estrogen receptor modulators, 
has emerged.  It is important to devise partial agonists for PPARγ, which will have beneficial effect 
in a particular tissue without causing adverse effects via its actions in other tissues.  Recently, there 
have been reports about investigation into such compounds.  The future of PPARγ research and 
harnessing its power for human well being may lie in these selective PPAR modulators.                    
